Background
==========

Worldwide, prostate cancer (adenocarcinoma) is the fourth most common cancer and is the second most common cancer in men \[[@b1-medscimonit-25-193]--[@b3-medscimonit-25-193]\]. Prostate cancer is also clinically heterogeneous and can be indolent or may have a highly aggressive course, requiring different treatment approaches \[[@b4-medscimonit-25-193],[@b5-medscimonit-25-193]\]. Increasing advances have been made in understanding the molecular basis for prostate cancer and distinguishing the different subtypes and the variable clinical outcomes. For example, androgen receptor-driven ETS gene fusion is an important molecular mechanism that allows the subclassification of prostate cancer, as are the activated gene fusions or mutations of RAS and RAF gene family members, a subtype of ETS-negative tumors \[[@b6-medscimonit-25-193]\]. An improved understanding of the genetic alterations that drive of prostate cancer at the molecular level may lead to new therapies that target for specific subtypes of prostate cancer.

The histone methyltransferase (HMT) family includes histone lysine methyltransferases (HKMTs) and histone/protein arginine methyltransferases (PRMTs). HMTs play crucial roles in epigenetic regulation, by controlling histone lysine methylation and demethylases. Currently, approximately 51 HMTs have been acknowledged identified in humans, with the primary functions being to catalyze the translocation of methyl moieties from S-adenosylmethionine (SAM) to histone lysine sites ([Supplementary Table 1](#s8-medscimonit-25-193){ref-type="supplementary-material"}) \[[@b7-medscimonit-25-193],[@b8-medscimonit-25-193]\]. Histone methylation can result in different biological effects according to the degree of histone methylated, including damage to chromatin structure, gene transcription, and alterations in cell mitosis, which may accelerate the development and progression of cancers \[[@b9-medscimonit-25-193]\]. There is now increasing evidence to validate the genetic roles of HMTs, including abnormal histone methylation, which may contribute to the genesis and progression of prostate cancer. For example, abnormal expression of the enhancer of zeste homolog 2 (EZH2) gene, resulting in an imbalance of H3K27me3 (trimethylation at lysine 27 of histone 3), has been shown to be associated with progression of prostate cancer and with castration-resistant prostate cancer (CRPC) \[[@b10-medscimonit-25-193],[@b11-medscimonit-25-193]\].

Although increasing advances have been made in the understanding of epigenetic regulation of cancers, the roles of HMTs in prostate cancer remain unknown. Therefore, the aims of this preliminary study were to evaluate HMT gene variants in the pathogenesis and prognosis of human prostate cancer, using *in vitro* cell studies and bioinformatics analysis, including the roles the 51 known HMT genes. The study included the analysis of data available from the Cancer Genome Atlas (TCGA) database, which allowed differential mRNA expression, copy number alteration (CNA), somatic gene mutation, and DNA methylation state to be identified with clinical outcome, including progression-free survival (PFS), in patients with prostate cancer.

Material and Methods
====================

Data sources
------------

The dataset of gene expression, copy number alteration (CNA), DNA methylation, gene mutation and clinic data for 51 human histone methyltransferases (HMTs) of 550 prostate adenocarcinoma samples available from the Cancer Genome Atlas (TCGA) (including 52 matched tumor and adjacent normal tissues) used in this study were downloaded from The University of California, Santa Cruz (UCSC) Cancer Genomics Browser (*<https://genome-cancer.ucsc.edu/>*). A total of 399 tumor samples, with clinical data, were chosen to perform an integrated analysis of 51 HMTs. Gene expression data were log^2^ (x+1) transformed from the RNA-Seq by Expectation-Maximization (RSEM) count estimates and DNA methylation data, shown as the β-value, and were profiled using the Infinium HumanMethylation27 platform (Illumina, San Diego, CA, USA).

The Gleason scoring system of histological grade was used as an indicator of the degree of tumor aggression and prognosis of prostate cancer, with increasing Gleason scores reflecting worse prognosis. Two patients with a Gleason score of 10 were incorporated into the patient group with a Gleason score of 9. For CNA data, homozygous deletion (Homedel), heterozygous deletion (Hetloss), diploid, low-level amplification (Gain) and high-level amplification (Amp) were indicated as −2, −1, 0, 1, and 2 respectively. Also, a gene copy number dataset of 150 previously published metastatic prostate cancer samples was downloaded from cBioPortal for Cancer Genomics (*<http://www.cbioportal.org>*) to compare CNAs in prostate cancer of different stage further, as tumor stage is also an indicator of prognosis ([Supplementary Table 2](#s9-medscimonit-25-193){ref-type="supplementary-material"}).

Statistical analysis
--------------------

Statistical analysis was performed using the R software (version 3.3.4), GraphPad Prism (version 7.01) and SPSS (version 18.0). A two-tailed paired t-test was performed to compare the different expression levels of 51 HMT genes in 52 matched prostate tumor tissues and adjacent normal tissues. The correlation analysis for CNA, mRNA expression and DNA methylation, mRNA expression of 51 HMTs in 399 sequenced prostate cancer patients were performed by Spearman correlation, Kendall rank correlation, and Pearson correlation analysis. Comparison between HMT expression profiles in prostate cancer samples with Gleason score was conducted by R statistical software using one-way analysis of variance (ANOVA). Correlation analysis and clustering methods analyzed the association between androgen receptor (AR) expression and HMT gene expression. Kaplan-Meier survival curve was conducted to investigate the impact of genetic alterations of different HMTs on patient survival. Univariate and multivariate Cox regression analysis was performed to identify factors associated with patient prognosis in 399 samples of prostate cancer by using the survival package in the R statistical software package.

Generation of a prognostic HMT gene signature
---------------------------------------------

The set of 399 patients with transcription, DNA methylation, CNA, mutation and clinical survival information was divided into groups for each gene that included high and low gene expression or methylation, deletion or amplification, diploid state, mutational and wild-type HMT genes, respectively. Each of the 51 gene expression features demonstrated a fit using a univariate Cox proportional-hazards analysis model without any adjustment, and 13 candidate features were generated at a p-value \<0.05 using the Wald test (Wald chi-squared test). These candidate features were further analyzed using multivariate Cox proportional hazards analysis model, with adjustment for age, T-stage, Gleason score, and androgen receptor (AR) expression. Eight features with significant correlation coefficients were identified, and a panel of the top four most significant HMT genes was finally identified.

The risk score of the panel of the top four most significant HMT genes was calculated according to the gene expression values and risk factors, to divide the patients with prostate cancer into two groups according to their scores, a high-risk and a low-risk group. Prediction across this panel was then pooled and performance assessed using the area under the receiver operating characteristics curve (AUROC). Kaplan-Meier plots were generated to evaluate their impact on clinical outcome. For CNA, features were selected to fit a univariate Cox proportional hazards analysis if frequencies of each type CNA (deletion or amplification) were more than 3%. Significant genes were identified to fit a multivariate Cox proportional hazards analysis model to assess their value as prognostic cancer biomarkers. Univariate and multivariate Cox proportional hazards analysis models were performed to analyze the prognostic value of DNA methylation and mutation in prostate cancer.

Data visualization
------------------

Data visualization tools including the ggplot2 data visualization package, pheatmap package in R, progression-free survival (PFS), receiver operator characteristic (ROC) curves, and meta packages of R (vision 3.3.4). Box plots of gene expression, histograms of changes in copy number, and Kaplan-Meier plots were visualized by GraphPad Prism (version 7.01). The mutational spectrum of the KMT2C and KMT2D genes was generated by the Oncoprint and MutationMapper tools (*<http://www.cbioportal.org/tools.jsp>*) on the cBioportal website \[[@b12-medscimonit-25-193]\].

Cell culture and transfection and real-time quantitative reverse transcription polymerase chain reaction (qRT-PCR)
------------------------------------------------------------------------------------------------------------------

The human prostate cancer cell line 22Rv1 was obtained from American Type Cell Culture (ATCC) (Catalog No. CRL-2505). Cells were cultured in RPMI 1640 media supplemented with 10% fetal bovine serum (FBS) (Gibco, Thermo Fisher Scientific, Waltham, MA, USA). Cells were maintained at 37°C in a humidified atmosphere with 5% CO~2~. Total RNA was extracted using TRIzol (Invitrogen, Carlsbad, CA, USA), as recommended by the manufacturer. The target sequence of the SETD5 gene was chosen as follows: GCUUGGAGGCUGAGGAGUU. The oligonucleotides corresponding to this target sequence were annealed and cloned into the EcoR1 and AgeI sites of the pLkO.1 plasmid (Addgene, Cambridge, MA, USA). The efficiency of SETD5 interference was determined by real-time quantitative reverse transcription polymerase chain reaction (qRT-PCR) using SYBR Premix Ex Taq II and SYBR Green I (Takara Biotechnology, Dalian, China). Quantitative primers of the SETD5 gene were as follows:

1.  Forward: GGACTGCCTTATGCTACGA;

2.  Reverse: GCCATCCTGAGAAAGACCACA.

Cell proliferation and migration assays
---------------------------------------

Cell proliferation of the human prostate cancer cell line 22Rv1 was evaluated by the MTS colorimetric cell proliferation assay (Sigma, St Louis, MO, USA) and a colony formation assay, according to the manufacturer's instructions, with each experiment performed in triplicate. A cell migration assay was used to assess the cell invasion capacity (Corning, NY, USA) with the assay performed in duplicate.

Results
=======

Identification of the expression profiles of histone methyltransferase (HMT) gene mRNA in prostate cancer
---------------------------------------------------------------------------------------------------------

The mRNA levels of the 51 histone methyltransferase (HMT) genes in 52 matched prostate tumor tissues and adjacent normal tissues were analyzed and presented as box plots. The Student's t-test was used to determine the significance of the gene expression levels. Compared with adjacent normal prostate tissues, mRNA levels of prostate cancer tissue of 14 HMT genes were identified that were significantly increased, including DOT1L, EZH2, EHMT1, KMT2B, PRDM10, PRDM12, PRDM15, SETD6, SETD7, SMYD2, SMYD3, SMYD5, SUV39H2, and WHSC1) (p\<0.001). Compared with adjacent normal tissues, mRNA levels of prostate cancer tissue of nine HMT genes were identified that were significantly decreased, including EZH1, MECOM, PRDM11, PRDM16, PRDM5, PRDM6, PRDM8, SETD4, and SMYD4 (p\<0.001) ([Figure 1](#f1-medscimonit-25-193){ref-type="fig"}). Also, mRNA expression levels of the PRDM13, PRDM14, PRDM7, PRDM9, and SMYD1 genes were at very low levels in both tumor tissues and normal prostate tissues. Twenty-one significantly fold-change (FC) genes with false discovery rates (FDR) with a p-value of \<0.05 were found using the Limma R software package for analyzing data from gene expression, including six 2.0-fold-change, three 1.5-fold-change, and eleven 1.2-fold-change genes, which were in accordance with 23 HMT genes previously described in the literature ([Supplementary Table 3](#s10-medscimonit-25-193){ref-type="supplementary-material"}).

To compare the differences between HMT gene expression profiles between Gleason score 6, 7, 8, and 9 prostate cancers, one-way analysis of variance (ANOVA) was performed, which identified 11 HMT genes that were significantly expressed: WHSC1, EZH2, PRDM12, KMT2D, SETD5, PRDM8, EHMT1, SUV420H2, PRDM10, PRDM6, and DOT1L (p \<0.001) ([Supplementary Figure 1](#s1-medscimonit-25-193){ref-type="supplementary-material"}, [Supplementary Table 4](#s11-medscimonit-25-193){ref-type="supplementary-material"}). Among those genes, PRDM6 and PRDM8 both showed a significantly negative correlation with the Gleason score. The EZH2, PRDM12, SUV420H2, WHSC1, PRDM10 and SETD5 genes showed a significantly positive correlation with the Gleason score ([Supplementary Figure 1](#s1-medscimonit-25-193){ref-type="supplementary-material"}, [Supplementary Figure 2](#s2-medscimonit-25-193){ref-type="supplementary-material"}). These findings indicated that alteration in mRNA expression levels of these genes in prostate cancer tissue samples were prognostic indicators in these cases of prostate cancer.

Changes in copy number alteration (CNA) of HMT genes in prostate carcinoma
--------------------------------------------------------------------------

Copy number alterations (CNAs) have previously been reported to be an important mechanism for activating oncogenes or inactivating tumor suppressor genes in the genesis and progression of human malignancy \[[@b13-medscimonit-25-193]\]. Therefore, CNAs of 51 HMT genes in 492 prostate cancer tissue samples were systematically analyzed, which identified six HMT genes: SETDB2, PRDM1, PRDM13, PRDM7, WHSC1L1, and PRDM5. These six genes showed homozygous deletion (Homedel) in more than 3% of prostate cancer tissue samples. Two HMT genes, PRDM14 and MECOM, showed high-level amplification (Amp) in more than 3% of prostate cancer samples ([Table 1](#t1-medscimonit-25-193){ref-type="table"}, [Supplementary Figure 3](#s3-medscimonit-25-193){ref-type="supplementary-material"}).

Further analysis of 51 HMT CNAs in prostate cancer tissue samples, with different Gleason scores, showed that increasing CNA events in prostate cancer were significantly correlated with a Gleason score of between 6 to 9 ([Figure 2A](#f2-medscimonit-25-193){ref-type="fig"}). The CNA frequencies of most HMT genes were positively correlated with the Gleason score, for both amplification and deletion alterations ([Supplementary Figure 4](#s4-medscimonit-25-193){ref-type="supplementary-material"}). Also, with increasing Gleason score, the average CNA events of HMT genes in each tumor tissue sample were all incrementally increased, except for the homozygous deletion (Homedel), which had a more stable level in prostate cancer tissue samples with different Gleason scores ([Figure 2C](#f2-medscimonit-25-193){ref-type="fig"}). The frequencies of CNA events in metastatic prostate cancer tissue samples were significantly increased when compared with primary prostate cancer tissue ([Supplementary Figure 5](#s5-medscimonit-25-193){ref-type="supplementary-material"}). These data indicated that, in the cases in this study, prostate cancers that had many more CNA events of the HMT genes had an increased tumor grade and worse clinical outcome.

The correlations between copy number alterations and expression of 51 HMT genes were analyzed in the 399 prostate cancer tissue samples that underwent sequence analysis. To obtain a weighted ranking for the correlation coefficients, the Spearman correlation, Kendall rank correlation, and Pearson correlation analysis were performed ([Table 2](#t2-medscimonit-25-193){ref-type="table"}). As shown in [Table 2](#t2-medscimonit-25-193){ref-type="table"}, gene expression levels of almost all HMT genes were positively correlated with CNAs, including two HMT genes, WHSC1L1 and SETDB2 with correlation coefficients \>0.5 (Spearman method, p\<0.0001) and four HMT genes, SETD6, SMYD4, EZH2 and SETDB1 with correlation coefficients \>0.3 (Spearman method, p\<0.0001). To further analyze the impact caused by CNAs on gene expression levels of HMTs, the frequency of amplification and deletion with higher or lower HMT mRNA levels in tissue samples were calculated separately. The frequency of amplification with higher HMT mRNA levels and deletion with lower HMT mRNA levels, were significantly increased in prostate cancer tissue compared with the normal prostate tissue (p\<0.0001, paired t-test). The difference between diploid tumor samples was non-significant ([Figure 2B](#f2-medscimonit-25-193){ref-type="fig"}, [Supplementary Table 5](#s12-medscimonit-25-193){ref-type="supplementary-material"}).

Methylation states of the HMT gene promoter CpG islands in prostate cancer
--------------------------------------------------------------------------

DNA methylation is a crucial regulator in tumor development, by altering mRNA expression. For 46 HMT genes, correlation analysis was performed to compare gene expression and promoter methylation in 399 prostate cancer tissue samples by three different statistical methods, the Spearman correlation analysis, Kendall rank correlation, and the Pearson correlation analysis. The results showed that the promoter methylation level of most HMT genes was negatively correlated with gene expression, including two HMT genes, PRDM8 and PRDM5, with an absolute value with the Spearman correlation coefficient \>0.5 (P\<0.0001) and one HMT gene, PRDM2 with the Spearman correlation coefficient \>0.3 (P\<0.0001). However, the methylation levels of the SETD4, PRDM12, and PRDM13 genes were all significantly correlated with gene expression levels, with a correlation coefficient \>0.3 (P\<0.0001) ([Table 2](#t2-medscimonit-25-193){ref-type="table"}).

The pheatmap package in R was plotted to show the promoter methylation profiles of 46 HMT genes in 50 paired prostate tumor and adjacent normal tissue samples. Most HMT genes had a lower promoter methylation level, but some HMT genes had a higher promoter methylation level, including the three genes, PRDM7, PRDM9, and SMYD1, which had low mRNA levels ([Figures 1](#f1-medscimonit-25-193){ref-type="fig"}, [3A](#f3-medscimonit-25-193){ref-type="fig"}). Further quantitative analysis of the methylation changes between matched tumor and adjacent normal prostate tissues, identified PRDM14, NSD1, and PRDM8 as the top three differentially methylated HMT genes in prostate cancer, by paired t-test and correlation analysis ([Supplementary Table 6](#s13-medscimonit-25-193){ref-type="supplementary-material"}). By combining the correlation analysis of mRNA and promoter methylation and the results of differential expression and methylation, the PRDM5 and PRDM8 genes were identified and underwent further analysis ([Figure 3B, 3C](#f3-medscimonit-25-193){ref-type="fig"}).

Analysis of the PRDM8 and PRDM5 differentially methylated HMT genes in prostate cancer
--------------------------------------------------------------------------------------

Promoter methylation of the PRDM8 gene was increased, even in the normal prostate tissues. However, the 1.5-fold-change was significantly increased in the tumor tissues resulting in significant alterations with gene expression (p\<0.0001, using a t-test). Different methylation levels of the PRDM8 gene were also correlated with clinical outcome in prostate tumor samples from 399 patients. Also, two CpG sites (cg04343891 and cg22961278) of the PRDM8 promoter were both differently methylated and significantly associated with PRDM8 gene expression ([Figure 3C](#f3-medscimonit-25-193){ref-type="fig"}).

Promoter methylation of the PRDM5 gene was decreased in the normal prostate tissues but was significantly increased in matched prostate cancer tissues. For PRDM5 gene expression, there were six CpG sites out of eight with a lower methylation level (β ≤0.1). In more than 90% of adjacent normal prostate tissues, and in more than 5% of tumor tissues, a higher methylation level was found (β ≥0.3). The average PRDM5 mRNA levels of the two groups (β ≥0.3 and β ≤0.1) in the 399 prostate cancer samples were compared for each CpG site. The results showed that PRDM5 was differently expressed between two groups for six CpG sites (p\<0.001 using a t-test) ([Table 3](#t3-medscimonit-25-193){ref-type="table"}). These data support that PRDM5 was a methylation silenced gene in prostate cancer in the cases in this study, which highlights the need for further studies to determine the potential treatment approaches for patients with different PRDM5 promoter methylation states \[[@b14-medscimonit-25-193]\].

Mutations of HMT genes in prostate cancer
-----------------------------------------

The KMT2C, KMT2D, ASH1L, KMT2A, and MECOM genes were the top five most frequently mutated HMT genes in prostate cancer in this study ([Table 1](#t1-medscimonit-25-193){ref-type="table"}, [Figure 4A](#f4-medscimonit-25-193){ref-type="fig"}). Integrated analysis of mutation profiles of KMT2C and KMT2D were performed in 425 primary prostate cancer samples. The results showed that a total of 23 KMT2C gene mutations and 21 KMT2D gene mutations were identified ([Figure 4B](#f4-medscimonit-25-193){ref-type="fig"}). A mutation map was performed to display the distribution and frequency of KMT2C and KMT2D mutations in 425 prostate cancers ([Figure 4C](#f4-medscimonit-25-193){ref-type="fig"}). A mutualy exclusivity relationship for copy number alterations and mutations of the top five mutated HMTs in prostate cancers are shown in [Figure 4D](#f4-medscimonit-25-193){ref-type="fig"}.

Co-expression of HMT genes with androgen receptors
--------------------------------------------------

Cluster analysis showed that high expression levels of several HMT genes, including ASH1L, SETD2, KMT2B, NSD1, KMT2C, SETD7, KMT2E, KMT2A, PRDM10, SETD5, PRDM2, PRDM4, and WHSC1L1 were significantly clustered in tumor tissue samples with high expression of androgen receptors when compared with tumor tissue samples with low expression of androgen receptors, which was determined by correlation analysis between androgen receptor and HMT mRNA levels ([Figure 5](#f5-medscimonit-25-193){ref-type="fig"}, [Supplementary Table 5](#s12-medscimonit-25-193){ref-type="supplementary-material"}). Notably, KMT2B, KMT2C, and KMT2E have been validated previously as having a role in the progression of castration-resistant prostate cancer (CRPC) \[[@b15-medscimonit-25-193]\]. These results showed that these genes, identified in the cases in this study, may be involved in the androgen receptor response pathway in prostate cancer, and their genetic alterations may function in the development of CRPC.

Alterations in HMT gene expression were associated with clinical outcome in patients with prostate cancer
---------------------------------------------------------------------------------------------------------

To study the clinical effects HMT gene variations on clinical outcome in patients with prostate cancer, the association between progression-free survival (PFS), CNA, mRNA levels, mutation and promoter methylation levels were examined in the 399 prostate cancer samples. Univariate Cox proportional hazards analysis was performed primarily to find potential HMT genes that were most relevant for further multivariate Cox proportional-hazards analysis, with p\<0.05. The results showed that amplification and deletion of most the most significant HMT genes were associated with poor clinical outcome (HR \>1). Nine HMT genes with increased levels of promoter methylation, and sixteen HMT genes with increased mRNA levels were identified as having a significant association with clinical outcome in the cases of prostate cancer included in this study ([Supplementary Table 7](#s14-medscimonit-25-193){ref-type="supplementary-material"}).

Patient age, the T-stage, Gleason score, and the expression level of the androgen receptor (AR) for 28 genetic alterations were identified by multivariate analysis (p\<0.1) ([Supplementary Table 8](#s18-medscimonit-25-193){ref-type="supplementary-material"}). The results showed that amplification of EHMT1, KMT2B, PRDM1, PRDM12, PRDM16, PRDM4, SETD1B, SETD8, SETDB1, SMYD1, SMYD2, SMYD5, and WHSC1L1 genes, and the deletion of EHMT2, SETD4, SETD6, SMYD1, SUV39H2, and WHSC1L1 genes, were significantly associated with reduced clinical outcome and PFS. Increased mRNA levels of EZH2, SETD5, and SUV420H2 genes, and lower mRNA levels of PRDM6, SMYD1, and PRDM16 genes were significantly associated with reduced clinical outcome and PFS in patients with prostate cancer. Increased methylation levels of NSD1 was significantly associated with a reduced patient overall survival (OS).

Of the 28 genetic alterations of HMT genes, mutations of KMT2C and KMT2D were investigated to show their clinical impact on prostate cancer samples using a forest plot ([Figure 6A](#f6-medscimonit-25-193){ref-type="fig"}). The most relevant HMT genes were selected by integrating the score of mRNA, CNA and promoter methylation associated survival, CNA frequencies, differential expression and methylation, correlation of HMT gene expression and CNAs, androgen receptor expression and Gleason score ([Figure 6B](#f6-medscimonit-25-193){ref-type="fig"}). Each of seven HMT genes, including EZH2, NSD1, RPDM12, SETD5, SETD6, SMYD1 and WHSC1L1, had a score of \>3, indicating that these seven HMT genes might play important roles in oncogenesis in prostate cancer. For these seven HMT genes, Kaplan-Meier curves were plotted and the results showed that amplification of EZH2 and SETD5 were associated with clinical outcome ([Figure 6C](#f6-medscimonit-25-193){ref-type="fig"}, [Supplementary Figure 6](#s6-medscimonit-25-193){ref-type="supplementary-material"}).

The four-gene HMT prognostic signature included EZH2, SETD5, SMYD1, and SUV420H2
--------------------------------------------------------------------------------

Expression of the four most significant HMT genes in terms of prognosis in prostate cancer, EZH2, SETD5, SMYD1, and SUV420H2, allowed a panel to be compiled to estimating their prognostic value for relapse of prostate cancer ([Figure 7A](#f7-medscimonit-25-193){ref-type="fig"}). Kaplan-Meier curves were plotted to show the prognostic value of this gene panel in the Cancer Genome Atlas (TCGA) cohort (n=399), by dividing the samples a high-risk and low-risk group ([Figure 7B](#f7-medscimonit-25-193){ref-type="fig"}). A time-dependent area under the receiver operating characteristics (AUROC) curve was used to assess the prognostic value of the four-gene HMT prognostic signature (EZH2, SETD5, SMYD1, and SUV420H2). The area under the curve (AUC) for the four-gene HMT prognostic signature model at one, three, and five years were 0.717, 0.690, and 0.720, respectively ([Figure 7C](#f7-medscimonit-25-193){ref-type="fig"}).

The SETD5 gene in the development and progression of prostate cancer
--------------------------------------------------------------------

The SETD5 gene expression was studied in the 399 samples of prostate cancer from TCGA data. The study samples were divided into low-expression and high-expression groups for SETD5 in tissue samples of prostate cancer, with the median value as the cutoff point. Five characteristics were analyzed in the low-expression and high-expression groups. The results showed that high SETD5 expression was correlated with high Gleason scores, increase serum levels of prostate-specific antigen (PSA), advanced T-stage, and the presence of lymph node metastases ([Table 4](#t4-medscimonit-25-193){ref-type="table"}).

The validate these results in prostate cancer, SETD5 was selected. There was no difference in the expression of SETD5 between tumor and adjacent normal tissues, but there was a difference in the expression of SETD5 between tissue samples of primary prostate cancer and metastatic prostate cancer in the GSE3325 dataset \[[@b16-medscimonit-25-193]\]. Also, serial experiments were performed to validate the role of the SETD5 gene in the 22Rv1 prostate cancer cell line. Following the establishment of the SETD5 knockdown cell line, colony formation assay, the MTS proliferation assay, and the transwell assay, SETD5 gene knockdown reduced cancer cell growth and migration in the 22Rv1 cells ([Figure 8](#f8-medscimonit-25-193){ref-type="fig"}).

Discussion
==========

Integrated genomic analyses of 51 histone methyltransferase (HMT) genes were performed in prostate adenocarcinoma samples, which were collected from the Cancer Genome Atlas (TCGA) database. In this study, there were eight main findings. First, nine significant fold-change (FC) genes with false discovery rates (FDR) \<0.05 were identified, including six 2.0-fold-change genes and three 1.5-fold-change genes. The expression of two HMT genes, PRDM6 and PRDM8, were significantly and negatively correlated with the Gleason score, while expression of the EZH2, PRDM12, SUV420H2, WHSC1, PRDM10 and SETD5 genes showed a significant positive correlation with the Gleason score. The mRNA levels of almost all HMT genes studied were significantly correlated with copy number, while expression of most HMT genes was negatively correlated with DNA methylation in prostate cancer in the cases in this study. An increased copy number alteration (CNA) in HMT genes in the prostate carcinoma tissue samples were positively correlated with a higher Gleason score and with a worse clinical outcome. Methylation of the PRDM8 gene was found to be significantly correlated with gene expression and clinical outcome. PRDM5, a methylation silencing gene, was identified as a potential gene for further investigation as a molecular target for prostate cancer. The SETD2 and ASH1L genes were found to have a potential role in the development of castration-resistant prostate cancer (CRPC). A panel of four HMT genes was identified as a gene prognostic signature, EZH2, SETD5, SMYD1, and SUV420H2, which could a potential prognostic biomarker panel. Also, knockdown of expression of the SETD5 gene reduced cell growth and migration of 22Rv1 human prostate carcinoma cells *in vitro*, indicating that the SETD5 gene may act as an oncogene in prostate cancer.

The HMT family includes histone lysine methyltransferases (HKMTs) and histone/protein arginine methyltransferases (PRMTs), which are enzymes that catalyze the transfer of methyl groups to specific substrates involving histones and specific proteins \[[@b7-medscimonit-25-193],[@b17-medscimonit-25-193]\]. The expression of HMT gene alterations has been identified in several human cancers and are thought to have an oncogenic role, including in prostate cancer \[[@b8-medscimonit-25-193]\]. One of the most studied HMT genes is the enhancer of zeste 2 polycomb repressive complex 2 subunit (EZH2), which is a protein-encoding gene. Genome and transcriptome alterations of EZH2 (amplification, overexpression, alternative splicing or mutation) have been validated to correlate with tumorigenesis and tumor progression in several types of cancers, including prostate cancer \[[@b18-medscimonit-25-193]--[@b21-medscimonit-25-193]\]. Also, increased EZH2 mRNA and protein levels have previously been shown to be associated with more rapid progression of prostate cancer, which may result from silencing of a specific cohort of genes by hypermethylation of specific histones \[[@b20-medscimonit-25-193],[@b22-medscimonit-25-193]\]. Another example of a prognostic gene is WHSC1 (also known as NSD2), which is an H3K36 histone methyltransferase \[[@b23-medscimonit-25-193]\]. Current studies indicate that the WHSC1 gene is frequently overexpressed in several cancers, including prostate cancer, and has as an oncogenic role \[[@b24-medscimonit-25-193],[@b25-medscimonit-25-193]\]. In the present study, overexpression of WHSC1 was more common in high Gleason score prostate cancers and negatively correlated with patient prognosis ([Supplementary Figure 1](#s1-medscimonit-25-193){ref-type="supplementary-material"}, [Supplementary Table 7](#s14-medscimonit-25-193){ref-type="supplementary-material"}). The findings of this study validated earlier studies that for individual HMT genes, several HMTs were identified as potential oncogene or tumor suppressor genes in prostate cancer.

Genetic alterations, including DNA methylation, to contribute to cellular transformation and carcinogenesis and are characteristic of most human malignancies \[[@b26-medscimonit-25-193]\]. Gene-specific DNA hypermethylation of promoter regions is associated with the inactivation of genes and downregulation of transcription \[[@b27-medscimonit-25-193],[@b28-medscimonit-25-193]\]. The PRDM8 and PRDM2 genes have been previously shown to be downregulated in invasive pituitary adenomas by whole-exome sequencing (WES), and they are both associated with cell proliferation and tumor recurrence \[[@b29-medscimonit-25-193]\]. Aberrant methylation of PRDM8 has been shown to be correlated with congenital dyskeratosis \[[@b30-medscimonit-25-193]\], but has not been previously studied in malignant tumors.

PRDM5 is a recognized tumor suppressor gene. Abnormal methylation of PRDM5 and levels of expression has been associated with carcinogenesis was validated in several cancers including cervical, colorectal, lung, and gastric cancers \[[@b31-medscimonit-25-193]--[@b33-medscimonit-25-193]\]. In some studies, PRDM5 has been identified as a target of epigenetic silencing, which supports the findings of the present study \[[@b34-medscimonit-25-193]\]. Differentially methylated CpG sites of PRDM13, which may contribute to more aggressive behavior in prostate cancer, were identified in tumor tissues of African American men \[[@b35-medscimonit-25-193]\]. In the present study, promoter methylation levels of PRDM13 and PRDM14 were significantly associated with clinical survival ([Supplementary Figure 7](#s7-medscimonit-25-193){ref-type="supplementary-material"}). Therefore, it is possible that when epigenetic modification caused by DNA methylation is reversible, carcinogenesis and cancer promotion caused by altered DNA methylation might be targeted by anti-methylation in cancer treatment.

The SETDB2 gene is one of HMT genes for histone H3 lysine 9 (H3K9) methylation and contains a commonly deleted gene at 13q in chronic lymphocytic leukemia (CLL) \[[@b36-medscimonit-25-193],[@b37-medscimonit-25-193]\]. In the present study, SETDB2 was the most frequently deleted HMT gene in prostate cancer, and this deletion was significantly related to clinical outcome ([Supplementary Figure 3](#s3-medscimonit-25-193){ref-type="supplementary-material"}). Studies in patients with CLL with deletion of SETDB2 have shown an associated with disease progression \[[@b37-medscimonit-25-193]\]. A recently reported study showed that overexpression of SETDB2 may contribute to disease progression in gastric cancer \[[@b38-medscimonit-25-193]\]. These previous studies support the findings of the present study ([Supplementary Table 5](#s12-medscimonit-25-193){ref-type="supplementary-material"}), and raise the possibility that CNAs function in tumorigenesis by several methods, regardless of their effects on gene expression.

The PRDM1 gene, localized at 6q21, has been previously shown to be a tumor suppressor gene in several human malignancies, especially in lymphoma. In diffuse large B-cell lymphoma, the PRDM1 gene can be inactivated by multiple mechanisms, including homozygous deletions, or missense or truncating mutations, which contribute to lymphomagenesis by blocking plasma cell differentiation \[[@b39-medscimonit-25-193],[@b40-medscimonit-25-193]\]. Additionally, deficiency of PRDM1 contributes to the maintenance of the phenotype and pathogenesis of gliomas \[[@b41-medscimonit-25-193]\]. PRDM14, a transcriptional regulator localized at 8q13, is overexpressed in several cancers and was also the most amplified HMT gene in the present study. However, as well as being associated with clinical survival, amplification of PRDM14 minimally contributed to its mRNA level ([Figure 2B](#f2-medscimonit-25-193){ref-type="fig"}, [Supplementary Figure 3](#s3-medscimonit-25-193){ref-type="supplementary-material"}). Overexpression of PRDM14 mRNA and protein as well as gene amplification have been reported in breast cancer, which correlated with disease progression and poor clinical outcome, indicating that alterations of PRDM14 could be a potential target for the treatment of breast cancer \[[@b42-medscimonit-25-193],[@b43-medscimonit-25-193]\]. In pancreatic cancer, overexpression of PRDM14 accompanied by deregulation of miR-125a-3p has been shown to be involved in cancer stem-like phenotypes and liver metastasis \[[@b44-medscimonit-25-193]\]. Similar results were also found in cases of non-small cell lung cancer (NSCLC) and leukemia \[[@b45-medscimonit-25-193],[@b46-medscimonit-25-193]\].

The KMT2C and KMT2D genes, the most commonly mutated HMT genes in human cancers, were also validated in the present study \[[@b47-medscimonit-25-193]\]. KMT2C and KMT2D are essential for regulation of enhancer activity by H3K4 mono-methylation, with mutation promoting tumorigenesis by deregulation of enhancer activity \[[@b48-medscimonit-25-193],[@b49-medscimonit-25-193]\]. Reduced expression of KMT2C and KMT2D has previously been shown to significantly correlate with improved outcome in pancreatic ductal adenocarcinoma, and *in vitro* studies have previously shown that the depleted level of these two HMTs attenuated cell proliferation by blocking cell-cycle and diminishing progression from G0--G1 \[[@b50-medscimonit-25-193]\]. In endometrioid endometrial carcinoma, the mutational status of KMT2C and KMT2D has been shown to correlate with the degree of myometrial invasion, which could be used to predict prognostic clinical outcome \[[@b51-medscimonit-25-193]\]. Also, a high level of expression of the KMT2D gene was associated with poor prognosis in patients with breast cancer, and KMT2D knockdown impaired proliferation and invasion in human breast cancer xenografts in mice \[[@b52-medscimonit-25-193]\]. In the present study, the expression of KMT2D was significantly associated with clinical outcome ([Supplementary Table 7](#s14-medscimonit-25-193){ref-type="supplementary-material"}), suggesting that KMT2D might function as an oncogene in prostate cancer.

Increasing published evidence has now shown that abnormal epigenetic regulation caused by genetic alterations of HMTs, including CNAs, mutation, ectopic expression, and methylation, contribute to tumorigenesis and progression in malignancy. Abnormal epigenetic dysregulation can be treated with targeted drugs or other treatments, and targeting these abnormalities provide potential personalized treatment approaches for cancer patients. Several inhibitors of selective HMTs, including DOT1L, EZH2, WHSC1, have been previously validated with targeted antitumor effects \[[@b53-medscimonit-25-193]\]. Also, because mixed-lineage leukemia (MLL) complex family members act as a crucial co-activator of the androgen receptor (AR) in advanced prostate cancer, a small-molecule inhibitor may improve the clinical outcome of patients with castration-resistant prostate cancer (CRPC) by targeting the MLL complex \[[@b15-medscimonit-25-193]\]. The results of the present study from the analysis 51 HMT genes systematically identified several HMT genes that have frequent genetic alterations or relate to clinical outcome in prostate cancer, and a four-gene HMT prognostic signature (EZH2, SETD5, SMYD1, and SUV420H2) was identified.

Conclusions
===========

The findings of this study have shown that epigenetic regulation of histone methyltransferases (HMTs) play important roles in the genesis and progression of prostate cancer. Further studies are required to determine the roles of HMTs in the diagnosis, treatment, and prognosis in prostate cancer.

Supplementary Materials
=======================

###### 

mRNA levels of 51 HMTs in different Gleason score prostate cancer samples. (**A**) Pheatmap of 51 HMTs expression profile in totally 399 prostate cancer samples. Normalized gene expression values by rows were median-centered prior to rows clustering based on Euclidean distance. One way ANOVA analysis were performed to compare the differences between Gleason score 6, 7, 8, and 9 prostate tumors. Significantly different expressed genes in prostate tumors are shown at the top, potential cancer related genes(p\<0.0001) are indicated by a red box. (**B**) Box plot show significantly four genes (PRDM6, PRDM8, PRDM12, EZH2) expression level(y-axis) positive or negative related to different Gleason score(x-axis).

###### 

mRNA levels of four HMTs in different Gleason score prostate cancers. Box plots show four genes (WHSC1, SUV420H2, PRDM10, SETD5) expression level (y-axis) significantly related to different Gleason score (x-axis).

###### 

CNAs frequencies of HMTs and their impact on clinical survival. (**A, B**) Bar graphs showed the most frequently altered HMTs. (**C, D**) Kaplan-Meier plotS of RFS proportion shows that deletion of SETDB2 and amplification of PRDM14 were significantly relevant to clinical outcome.

###### 

HMTs copy number alteration profiles in different Gleason score prostate samples. Pheatmap shows that CNAs frequencies of HMTs were tendentiously positive related to Gleason score, interestingly, both for amplification and deletion alterations.

###### 

HMTs copy number alteration profiles in different stage prostate cancers. (**A**) Pheatmap shows that increasing CNA events of 51 HMTs correlated with different stages of prostate cancers. (**B**) Histogram shown average CNAs per sample in different stage prostate cancers.

###### 

Kaplan-Meier plots of RFS proportion show that different impacts caused by CNAs and ectopic gene expression of significant HMTs (PRDM12, SETD6, SMYD1, WHSC1L1) on clinical survival.

###### 

Kaplan-Meier plots of RFS proportion show that different impactS caused by methylation level of significant HMTs (NSD1, PRDM13,PRDM14, KMT2B) on clinical survival.

###### 

Summary of identified human HMTs and their histone substrates.

  Official symbol   Other aliases      Gene ID   Gene location   Histone substrates
  ----------------- ------------------ --------- --------------- ---------------------
  ASH1L             KMT2H; ASH1L1      55870     1q22            H3K4me1/3, H3K36me2
  DOT1L             DOT1; KMT4         84444     19p13.3         H3K79me1/2/3
  EHMT1             GLP1; KMT1D        79813     9q34.3          H3K9me1/2
  EHMT2             G9A; KMT1C         10919     6p21.31         H3K9me1/2
  EZH1              KMT6B              2145      17q21.2         H3K27me2/3
  EZH2              KMT6A              2146      7q36.1          H3K27me2/3
  KMT2A             MLL                4297      11q23.3         H3K4me1/2/3
  KMT2B             MLL2               9757      19q13.12        H3K4me1/2/3
  KMT2C             MLL3               58508     7q36.1          H3K4me1/2/3
  KMT2D             MLL4               8085      12q13.12        H3K4me1/2/3
  KMT2E             MLL5               55904     7q22.3          H3K4
  MECOM             PRDM3; MDS1-EVI1   2122      **3q26.2**      H3K9me1
  NSD1              KMT3B              64324     5q35.2          H3K36me1/2
  PRDM1             BLIMP16            639       6q21            
  PRDM10            PFM7               56980     11q24.3         
  PRDM11            PFM8               56981     11p11.2         
  PRDM12            PFM9               59335     9q34.12         
  PRDM13            PFM10              59336     6q16.2          
  PRDM14            PFM11              63978     **8q13.3**      
  PRDM15            PFM15              63977     21q22.3         
  PRDM16            MEL1; PFM13        63976     1p36.32         H3K9me1
  PRDM2             RIZ; KMT8          7799      1p36.21         H3K9me1/2/3
  PRDM4             PFM1               11108     12q23.3         
  PRDM5             PFM2               11107     4q27            H3K9me2
  PRDM6                                93166     5q23.2          
  PRDM7             PFM4; ZNF910       11105     16q24.3         
  PRDM8             PFM5               56978     4q21.21         H3k9me3
  PRDM9             PFM6; MEISETZ      56979     5p14.2          H3K4me3
  SETD1A            KMT2F; SET1A       9739      16p11.2         H3K4me1/2/3
  SETD1B            KMT2G; SET1B       23067     12q24.31        H3K4me1/2/3
  SETD2             HYPB; SET2         29072     3p21.31         H3K36me1/2/3
  SETD3             C14orf154          84193     14q32.2         
  SETD4             C21orf18           54093     21q22.12        
  SETD5                                55209     3p25.3          
  SETD6                                79918     16q21           
  SETD7             KMT7; SET7/9       80854     4q31.1          H3K4me1
  SETD8             KMT5A; PR-SETD7    387893    12q24.31        H4K20me1
  SETDB1            ESET; KMT1E        9869      1q21.3          H3K9me1/2/3
  SETDB2            CLL8; KMT1F        83852     13q14.2         H3K9
  SETMAR            METNASE            6419      3p26.1          H3K36
  SMYD1             KMT3D; ZMYND18     150572    2p11.2          H3K4
  SMYD2             KMT3C; ZMYND14     56950     1q32.3          H3K4; H3K36me2
  SMYD3             KMT3E; ZMYND1;     64754     1q44            H3K4me2/3
  SMYD4             ZMYND21            114826    17p13.3         
  SMYD5             RRG1; ZMYND23      10322     2p13.2          
  SUV39H1           KMT1A              6839      Xp11.23         H3K9me2/3
  SUV39H2           KMT1B              79723     10p13           H3K9me2/3
  SUV420H1          KMT5B; CGI-85      51111     **11q13.2**     H4K20me2/3
  SUV420H2          KMT5C              84787     19q13.42        H4K20me2/3
  WHSC1             NSD2; MMSET        7468      4p16.3          H3K36me1/2
  WHSC1L1           NSD3               54904     **8p11.23**     H3K36me1/2; H3K4

###### 

Number of samples from TCGA used in our analyses. For the RNA-Seq data and methylation data the number of tumor and normal samples are indicated. We also indicate the number of tumor samples with mutation data, and with copy number variation (CNV) data.

  Acronym             Tumor type                Data type       Paired samples   Total tumor samples   Metastatic PRAD   
  ------------------- ------------------------- --------------- ---------------- --------------------- ----------------- ---
  PRAD                Prostate adenocarcinoma    RNA seq data   52               52                    497               0
   CpG data(46HMTs)   50                        50              499              0                                       
   CNV data           0                         0               492              150                                     
   Mutation data      0                         0               425              0                                       
  Quadruple overlap   0                         0               399              0                                       

###### 

Summary of expression fold-changed genes with false discovery rates (FDR) \<0.05.

            Gene     logFC    AveExpr   t          P.value    FDR        B
  --------- -------- -------- --------- ---------- ---------- ---------- --------
  2.0FC     PRDM8    −1.526   9.088     −5.666     1.30E-07   8.08E-07   6.880
  MECOM     −1.216   8.501    −6.737    9.03E-10   9.65E-09   11.736     
  PRDM16    −1.129   4.769    −4.080    8.80E-05   2.54E-04   0.592      
  SMYD1     −1.033   1.099    −2.254    2.63E-02   4.55E-02   −4.668     
  PRDM12    1.016    1.348    7.227     8.37E-11   2.18E-09   14.071     
  EZH2      1.433    5.944    8.778     3.43E-14   1.78E-12   21.754     
  1.5FC     PRDM5    −0.932   5.892     −5.874     5.10E-08   3.79E-07   7.790
  PRDM11    −0.904   4.968    −6.843    5.42E-10   9.40E-09   12.235     
  PRDM6     −0.800   5.200    −3.475    7.44E-04   1.93E-03   −1.424     
  1.2FC     EZH1     −0.542   9.792     −6.731     9.28E-10   9.65E-09   11.709
  SMYD4     −0.371   8.315    −4.951    2.84E-06   1.23E-05   3.885      
  PRDM15    0.320    7.400    5.011     2.21E-06   1.05E-05   4.127      
  PRDM10    0.337    7.990    4.292     3.96E-05   1.47E-04   1.353      
  WHSC1     0.367    9.820    5.064     1.77E-06   9.20E-06   4.345      
  SETD7     0.429    11.984   4.351     3.16E-05   1.26E-04   1.571      
  KMT2B     0.432    11.025   3.438     8.42E-04   1.99E-03   −1.540     
  SMYD2     0.433    8.849    4.118     7.65E-05   2.34E-04   0.725      
  SUV39H2   0.455    7.832    4.273     4.26E-05   1.48E-04   1.284      
  SMYD3     0.509    7.713    5.885     4.84E-08   3.79E-07   7.841      
  DOT1L     0.567    8.862    5.649     1.40E-07   8.08E-07   6.807      

###### 

Summary for association of Gleason score and AR expression with HMTs expression profile.

  Gleason score/HMTs expression (one-way ANOVA, top 11 HMTs were filled with yellow color)   AR/HMTs expression (top 13 significant HMTs with the green padding were also in the same clustering)                          
  ------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------ ---------- ----------- -------
  ASH1L                                                                                      4.49E-01                                                                                               ASH1L      4.94E-155   0.871
  DOT1L                                                                                      7.57E-04                                                                                               DOT1L      1.43E-06    0.214
  EHMT1                                                                                      2.78E-04                                                                                               EHMT1      9.08E-46    0.579
  EHMT2                                                                                      8.27E-01                                                                                               EHMT2      2.19E-12    0.308
  EZH1                                                                                       2.11E-02                                                                                               EZH1       9.07E-01    0.005
  EZH2                                                                                       1.35E-12                                                                                               EZH2       1.23E-03    0.145
  KMT2A                                                                                      4.68E-01                                                                                               KMT2A      5.77E-97    0.766
  KMT2B                                                                                      1.40E-01                                                                                               KMT2B      1.24E-128   0.832
  KMT2C                                                                                      3.70E-01                                                                                               KMT2C      5.65E-122   0.820
  KMT2D                                                                                      2.60E-05                                                                                               KMT2D      5.63E-32    0.494
  KMT2E                                                                                      1.92E-01                                                                                               KMT2E      4.56E-105   0.785
  MECOM                                                                                      2.21E-01                                                                                               MECOM      1.31E-06    0.215
  NSD1                                                                                       5.49E-02                                                                                               NSD1       8.13E-127   0.829
  PRDM1                                                                                      3.20E-01                                                                                               PRDM1      7.06E-13    0.315
  PRDM10                                                                                     4.92E-04                                                                                               PRDM10     1.21E-87    0.741
  PRDM11                                                                                     2.71E-03                                                                                               PRDM11     6.96E-12    0.301
  PRDM12                                                                                     5.82E-06                                                                                               PRDM12     1.80E-01    0.060
  PRDM13                                                                                     4.62E-01                                                                                               PRDM13     2.76E-01    0.049
  PRDM14                                                                                     4.33E-01                                                                                               PRDM14     7.13E-01    0.017
  PRDM15                                                                                     5.90E-02                                                                                               PRDM15     6.48E-04    0.152
  PRDM16                                                                                     6.83E-01                                                                                               PRDM16     7.48E-01    0.014
  PRDM2                                                                                      3.85E-01                                                                                               PRDM2      2.77E-70    0.686
  PRDM4                                                                                      4.69E-01                                                                                               PRDM4      3.72E-54    0.620
  PRDM5                                                                                      9.29E-02                                                                                               PRDM5      3.45E-19    0.387
  PRDM6                                                                                      6.89E-04                                                                                               PRDM6      4.26E-03    0.128
  PRDM7                                                                                      3.84E-01                                                                                               PRDM7      5.38E-03    0.125
  PRDM8                                                                                      6.63E-05                                                                                               PRDM8      8.01E-01    0.011
  PRDM9                                                                                      5.35E-01                                                                                               PRDM9      7.02E-01    0.017
  SETD1A                                                                                     3.29E-01                                                                                               SETD1A     3.63E-02    0.094
  SETD1B                                                                                     9.31E-03                                                                                               SETD1B     1.11E-44    0.573
  SETD2                                                                                      2.64E-02                                                                                               SETD2      3.47E-129   0.833
  SETD3                                                                                      3.48E-01                                                                                               SETD3      8.77E-01    0.007
  SETD4                                                                                      1.29E-03                                                                                               SETD4      2.56E-22    0.417
  SETD5                                                                                      2.64E-05                                                                                               SETD5      6.88E-78    0.712
  SETD6                                                                                      5.42E-02                                                                                               SETD6      7.32E-01    0.015
  SETD7                                                                                      4.45E-01                                                                                               SETD7      9.24E-106   0.787
  SETD8                                                                                      2.48E-03                                                                                               SETD8      5.01E-09    0.258
  SETDB1                                                                                     1.24E-02                                                                                               SETDB1     1.60E-13    0.323
  SETDB2                                                                                     3.50E-01                                                                                               SETDB2     1.61E-02    0.108
  SETMAR                                                                                     1.63E-01                                                                                               SETMAR     2.40E-34    0.511
  SMYD1                                                                                      1.97E-01                                                                                               SMYD1      9.40E-01    0.003
  SMYD2                                                                                      4.78E-01                                                                                               SMYD2      2.22E-01    0.055
  SMYD3                                                                                      5.14E-01                                                                                               SMYD3      1.14E-09    0.269
  SMYD4                                                                                      3.06E-01                                                                                               SMYD4      9.99E-20    0.392
  SMYD5                                                                                      9.71E-01                                                                                               SMYD5      8.87E-21    0.402
  SUV39H1                                                                                    3.77E-01                                                                                               SUV39H1    4.30E-19    0.386
  SUV39H2                                                                                    4.21E-02                                                                                               SUV39H2    1.03E-05    0.196
  SUV420H1                                                                                   6.57E-03                                                                                               SUV420H1   3.81E-42    0.559
  SUV420H2                                                                                   3.88E-04                                                                                               SUV420H2   7.67E-26    0.447
  WHSC1                                                                                      2.89E-14                                                                                               WHSC1      4.06E-31    0.488
  WHSC1L1                                                                                    5.19E-01                                                                                               WHSC1L1    6.19E-47    0.585

###### 

Summary of correlation between CNAs frequencied and gene expression levels.

  Gene       Amplification   Deletion   Diploid   Total amplification   Total deletion   Amplification and expressed higher (%)   Amplification and expressed lower (%)   Deletion and expressed higher (%)   Deletion and expressed lower (%)                    
  ---------- --------------- ---------- --------- --------------------- ---------------- ---------------------------------------- --------------------------------------- ----------------------------------- ---------------------------------- -------- ------- --------
  ASH1L      19              8          0         8                     183              181                                      27                                      8                                   70.37                              29.63    0.00    100.00
  DOT1L 4    1               11         19        179                   185              5                                        30                                      80.00                               20.00                              36.67    63.33   
  EHMT1      35              11         3         5                     183              162                                      46                                      8                                   76.09                              23.91    37.50   62.50
  EHMT2      8               4          5         10                    185              187                                      12                                      15                                  66.67                              33.33    33.33   66.67
  EZH1       3               1          13        37                    161              184                                      4                                       50                                  75.00                              25.00    26.00   74.00
  EZH2       58              15         2         6                     178              140                                      73                                      8                                   79.45                              20.55    25.00   75.00
  KMT2A      12              10         14        15                    174              174                                      22                                      29                                  54.55                              45.45    48.28   51.72
  KMT2B      6               3          10        6                     190              184                                      9                                       16                                  66.67                              33.33    62.50   37.50
  KMT2C      39              35         10        11                    153              151                                      74                                      21                                  52.70                              47.30    47.62   58.38
  KMT2D      6               5          8         8                     186              186                                      11                                      16                                  54.55                              45.45    50.00   50.00
  KMT2E      39              37         3         4                     158              158                                      76                                      7                                   51.32                              48.68    42.86   57.14
  MECOM      36              26         3         4                     169              161                                      62                                      7                                   58.06                              41.94    42.86   57.14
  NSD1       16              6          5         5                     188              179                                      22                                      10                                  72.73                              27.27    50.00   50.00
  PRDM1      2               0          62        60                    139              136                                      2                                       122                                 100.00                             0.00     50.82   49.18
  PRDM10     18              6          6         13                    180              176                                      24                                      19                                  75.00                              25.00    31.58   68.42
  PRDM11     8               8          6         20                    171              186                                      16                                      26                                  50.00                              50.00    23.08   76.92
  PRDM12     33              11         1         9                     179              166                                      44                                      10                                  75.00                              25.00    10.00   90.00
  PRDM13     0               5          7         118                   189              80                                       5                                       125                                 0.00                               100.00   5.60    94.40
  PRDM14     16              96         0         2                     270              15                                       112                                     2                                   14.29                              85.71    0.00    100.00
  PRDM15     14              4          8         18                    177              178                                      18                                      26                                  77.78                              22.22    30.77   69.23
  PRDM16     3               4          13        16                    179              184                                      7                                       29                                  42.86                              57.14    44.83   55.17
  PRDM2      2               0          9         26                    173              189                                      2                                       35                                  100.00                             0.00     25.71   74.29
  PRDM4      18              2          6         13                    184              176                                      20                                      19                                  90.00                              10.00    31.58   68.42
  PRDM5      4               6          7         29                    164              189                                      10                                      36                                  40.00                              60.00    19.44   80.56
  PRDM6      7               6          6         26                    167              187                                      13                                      32                                  53.85                              46.15    18.75   81.25
  PRDM7      1               3          42        103                   160              90                                       40                                      145                                 25.00                              75.00    28.97   71.03
  PRDM8      4               7          5         10                    182              191                                      11                                      15                                  36.36                              63.64    33.33   66.67
  PRDM9      6               19         2         8                     347              17                                       25                                      10                                  24.00                              76.00    20.00   80.00
  SETD1A     20              3          14        11                    185              166                                      23                                      25                                  86.96                              13.04    56.00   44.00
  SETD1B     13              3          11        17                    179              176                                      16                                      28                                  81.25                              18.75    39.29   60.71
  SETD2      17              7          3         16                    176              180                                      24                                      19                                  70.83                              29.17    15.79   84.21
  SETD3      8               2          6         25                    172              186                                      10                                      31                                  80.00                              20.00    19.35   80.65
  SETD4      14              3          4         13                    183              182                                      17                                      17                                  82.35                              17.65    23.53   76.47
  SETD5      17              8          3         25                    166              180                                      25                                      28                                  68.00                              32.00    10.71   89.29
  SETD6      6               0          15        78                    121              179                                      6                                       93                                  100.00                             0.00     16.13   83.87
  SETD7      7               4          3         14                    181              190                                      11                                      17                                  63.64                              36.36    17.65   82.35
  SETD8      11              3          6         25                    171              183                                      14                                      31                                  78.57                              21.43    19.35   80.65
  SETDB1     26              2          1         1                     196              173                                      28                                      2                                   92.86                              7.14     50.00   50.00
  SETDB2     1               1          34        131                   67               165                                      2                                       165                                 50.00                              50.00    20.61   79.39
  SETMAR     17              8          5         16                    175              178                                      25                                      21                                  68.00                              32.00    23.81   76.19
  SMYD1      2               10         4         16                    279              88                                       12                                      20                                  16.67                              83.33    20.00   80.00
  SMYD2      12              9          4         16                    174              184                                      21                                      20                                  57.14                              42.86    20.00   80.00
  SMYD3      18              3          3         11                    185              179                                      21                                      14                                  85.71                              14.29    21.43   78.57
  SMYD4      5               0          9         58                    141              186                                      5                                       67                                  100.00                             0.00     13.43   86.57
  SMYD5      11              1          5         19                    179              184                                      12                                      24                                  91.67                              8.33     20.83   79.17
  SUV39H1    4               5          13        7                     187              183                                      9                                       20                                  44.44                              55.56    65.00   35.00
  SUV39H2    12              2          4         29                    168              184                                      14                                      33                                  85.71                              14.29    12.12   87.88
  SUV420H1   26              7          0         6                     186              174                                      33                                      6                                   174.79                             21.21    0.00    100.0
  SUV420H2   13              1          10        4                     194              177                                      14                                      14                                  92.86                              7.114    71.43   28.57
  WHSC1      14              2          9         12                    185              177                                      16                                      21                                  87.50                              12.50    42.86   57.14
  WHSC1L1    44              7          18        111                   81               138                                      51                                      129                                 86.27                              13.73    13.95   86.05

###### 

Summary for differential promoter methylation HMTs in paired normal and tumor tissues.

  Gene       Differential methylation analysis of 46 HMTs   Paired T-test                                            
  ---------- ---------------------------------------------- --------------- --------- ---------- ---------- -------- ----------
  PRDM14     −0.201                                         0.320           −11.345   1.30E-19   6.09E-18   33.276   1.75E-17
  NSD1       −0.142                                         0.421           −9.479    1.49E-15   3.50E-14   23.928   2.44E-13
  PRDM8      −0.146                                         0.432           −8.138    1.20E-12   1.89E-11   17.253   6.68E-12
  EZH1       −0.024                                         0.103           −7.529    2.41E-11   2.83E-10   14.277   1.61E-10
  PRDM13     −0.121                                         0.306           −7.276    8.19E-11   7.70E-10   13.062   6.16E-12
  PRDM6      −0.065                                         0.158           −6.626    1.81E-09   1.42E-08   9.998    6.49E-10
  PRDM12     −0.047                                         0.119           −6.586    2.18E-09   1.47E-08   9.813    3.76E-10
  SETD3      0.061                                          0.604           6.222     1.18E-08   6.93E-08   8.149    3.26E-08
  PRDM5      −0.093                                         0.117           −5.224    9.70E-07   5.07E-06   3.821    2.09E-06
  KMT2B      0.057                                          0.551           4.548     1.54E-05   7.22E-05   1.136    5.32E-06
  PRDM15     −0.012                                         0.157           −4.393    2.81E-05   1.20E-04   0.554    2.38E-05
  SETD5      0.037                                          0.474           3.924     1.61E-04   6.31E-04   −1.122   6.03E-05
  PRDM7      0.041                                          0.537           3.845     2.13E-04   7.71E-04   −1.391   1.73E-04
  WHSC1      0.023                                          0.463           3.619     4.67E-04   1.57E-03   −2.136   2.21E-04
  SETDB1     0.014                                          0.140           3.088     2.61E-03   8.19E-03   −3.749   1.03E-04
  EHMT2      0.004                                          0.097           2.887     4.78E-03   1.40E-02   −4.307   3.23E-04
  MECOM      −0.016                                         0.151           −2.837    5.52E-03   1.53E-02   −4.439   3.26E-03
  KMT2E      −0.031                                         0.417           −2.721    7.69E-03   1.72E-02   −4.741   5.31E-03
  SETD1A     0.009                                          0.127           2.725     7.60E-03   1.72E-02   −4.731   6.35E-03
  SMYD1      0.050                                          0.805           2.747     7.14E-03   1.72E-02   −4.674   5.86E-03
  PRDM9      0.071                                          0.586           2.735     7.39E-03   1.72E-02   −4.705   9.94E-04
  SUV420H1   −0.008                                         0.225           −2.700    8.16E-03   1.74E-02   −4.795   2.43E-03
  PRDM2      0.007                                          0.431           2.583     1.13E-02   2.30E-02   −5.087   3.74E-03
  PRDM11     0.019                                          0.845           2.497     1.42E-02   2.77E-02   −5.293   9.22E-03
  PRDM4      −0.004                                         0.062           −2.420    1.73E-02   3.26E-02   −5.473   1.23E-02
  PRDM10     0.025                                          0.564           2.390     1.87E-02   3.38E-02   −5.542   2.59E-02
  DOT1L      0.002                                          0.036           2.290     2.42E-02   4.20E-02   −5.766   9.03E-03
  SMYD5      0.008                                          0.230           1.982     5.02E-02   8.43E-02   −6.401   3.76E-02
  SETD7      0.003                                          0.057           1.902     6.00E-02   9.73E-02   −6.551   2.41E-02
  SETMAR     −0.005                                         0.173           −1.523    1.31E-01   2.05E-01   −7.188   8.77E-02
  SETD4      0.001                                          0.032           1.425     1.57E-01   2.39E-01   −7.331   1.30E-01
  KMT2D      0.003                                          0.079           1.318     1.91E-01   2.71E-01   −7.476   5.25E-02
  SETDB2     0.005                                          0.905           1.335     1.85E-01   2.71E-01   −7.454   1.62E-01
  WHSC1L1    −0.004                                         0.151           −1.244    2.17E-01   2.99E-01   −7.571   2.39E-01
  SUV39H2    0.001                                          0.041           1.191     2.36E-01   3.09E-01   −7.634   2.32E-01
  AR         0.005                                          0.316           1.191     2.36E-01   3.09E-01   −7.634   1.74E-01
  PRDM1      −0.014                                         0.148           −1.147    2.54E-01   3.23E-01   −7.686   2.81E-01
  SETD2      0.001                                          0.036           0.996     3.22E-01   3.98E-01   −7.847   2.55E-01
  ASH1L      0.003                                          0.473           0.978     3.31E-01   3.98E-01   −7.865   2.85E-01
  SUV420H2   −0.001                                         0.025           −0.908    3.66E-01   4.30E-01   −7.931   3.20E-01
  SMYD2      −0.002                                         0.062           −0.828    4.10E-01   4.70E-01   −8.001   3.54E-01
  SMYD3      −0.002                                         0.413           −0.685    4.95E-01   5.29E-01   −8.109   4.27E-01
  EZH2       −0.001                                         0.295           −0.703    4.84E-01   5.29E-01   −8.097   3.90E-01
  SETD6      −0.001                                         0.039           −0.717    4.75E-01   5.29E-01   −8.086   3.54E-01
  SETD8      0.000                                          0.030           −0.373    7.10E-01   7.42E-01   −8.275   6.77E-01
  KMT2A      0.000                                          0.030           0.107     9.15E-01   9.35E-01   −8.340   8.71E-01
  SUV39H1    0.000                                          0.115           0.057     9.55E-01   9.55E-01   −8.344   9.52E-01

###### 

Summary of uniivariate analysis of RFS for **amplification of 51 HMTs** in prostate cancer.

  Gene       p-Value   HR      95% CI   Count amplification   Count diploid   Count percentage   
  ---------- --------- ------- -------- --------------------- --------------- ------------------ ------
  PRDM14     0.0081    1.860   1.185    2.919                 112             285                28.2
  WHSC1L1    0.0051    2.401   1.330    4.332                 51              219                18.9
  EHMT1      0.0001    3.133   1.876    5.232                 46              345                11.8
  PRDM12     0.0002    3.022   1.795    5.090                 44              345                11.3
  SUV420H1   0.0075    2.390   1.336    4.273                 33              360                8.4
  SETDB1     0.0031    2.860   1.543    5.303                 28              369                7.1
  SETD1A     0.0157    2.520   1.286    4.938                 23              351                6.1
  SMYD2      0.0188    2.723   1.304    5.686                 21              358                5.5
  PRDM4      0.0015    3.808   1.882    7.703                 20              360                5.3
  PRDM15     0.0445    2.214   1.095    4.478                 18              355                4.8
  SETD1B     0.0006    4.815   2.279    10.173                16              355                4.3
  WHSC1      0.0467    2.299   1.098    4.813                 16              362                4.2
  SETD8      0.0100    3.722   1.596    8.682                 14              354                3.8
  SUV420H2   0.0499    2.409   1.099    5.281                 14              371                3.6
  SMYD5      0.0009    5.127   2.330    11.284                12              363                3.2
  SMYD1      0.0005    5.729   2.599    12.630                12              367                3.2
  EHMT2      0.0278    2.969   1.281    6.882                 12              372                3.1
  KMT2B      0.0311    3.242   1.300    8.084                 9               374                2.3
  PRDM16     0.0029    7.508   2.674    21.079                7               363                1.9
  DOT1L      0.0358    3.657   1.323    10.106                5               364                1.4
  PRDM1      0.0219    9.340   2.227    39.178                2               275                0.7
  SETD3      0.2315    0.362   0.050    2.622                 10              358                2.7
  PRDM7      0.3568    0.000   0.000    Inf                   4               250                1.6
  SETD4      0.0502    2.263   1.083    4.731                 17              365                4.5
  PRDM8      0.0507    2.393   1.096    5.227                 11              373                2.9
  PRDM13     0.0664    3.720   1.147    12.065                5               269                1.8
  ASH1L      0.0749    1.998   0.993    4.017                 27              364                6.9
  PRDM9      0.0840    1.953   0.971    3.926                 25              364                6.4
  SETD6      0.0854    4.711   1.119    19.832                6               300                2.0
  PRDM2      0.1026    9.419   1.273    69.698                2               362                0.5
  NSD1       0.1187    1.887   0.905    3.937                 22              367                5.7
  MECOM      0.1318    1.543   0.898    2.653                 62              330                15.8
  SMYD4      0.1402    3.589   0.868    14.839                5               327                1.5
  EZH2       0.1436    1.470   0.891    2.426                 73              318                18.7
  KMT2E      0.1859    1.418   0.857    2.347                 76              316                19.4
  PRDM10     0.1868    1.649   0.821    3.311                 24              356                6.3
  KMT2C      0.1870    1.418   0.856    2.349                 74              304                19.6
  SETMAR     0.1931    1.746   0.801    3.809                 25              353                6.6
  KMT2A      0.1991    1.674   0.802    3.494                 22              348                5.9
  SETD5      0.2196    1.688   0.774    3.679                 25              346                6.7
  SMYD3      0.2284    1.742   0.754    4.024                 21              364                5.5
  PRDM5      0.2589    1.894   0.688    5.217                 10              353                2.8
  SUV39H1    0.2972    1.975   0.620    6.296                 9               370                2.4
  SETD2      0.3418    1.538   0.666    3.551                 24              356                6.3
  PRDM11     0.3802    1.543   0.620    3.839                 16              357                4.3
  SETD7      0.6018    1.383   0.433    4.411                 11              371                2.9
  SETDB2     0.6704    1.601   0.211    12.166                2               232                0.9
  PRDM6      0.6765    1.292   0.406    4.117                 13              354                3.5
  EZH1       0.6774    1.570   0.216    11.403                4               345                1.1
  KMT2D      0.7397    1.224   0.385    3.895                 11              372                2.9
  SUV39H2    0.9204    0.943   0.295    3.016                 14              352                3.8

###### 

Summary of uniivariate analysis of RFS for **deletion of 51 HMTs** in prostate cancer.

  Gene       p-Value   HR      95% CI   Count amplification   Count diploid   Count percentage   
  ---------- --------- ------- -------- --------------------- --------------- ------------------ ------
  DOT1L      0.0363    2.053   1.103    3.821                 30              364                7.6
  EHMT2      0.0356    2.801   1.211    6.478                 15              372                3.9
  PRDM7      0.0055    1.881   1.205    2.934                 145             250                36.7
  SETD4      0.0042    3.905   1.778    8.576                 17              365                4.5
  SETD6      0.0016    2.161   1.364    3.423                 93              300                23.7
  SETDB2     0.0082    1.833   1.164    2.886                 165             232                41.6
  SMYD1      0.0102    2.847   1.409    5.756                 20              367                5.2
  SUV39H2    0.0014    2.710   1.558    4.711                 33              352                8.6
  SUV420H2   0.0121    2.947   1.411    6.159                 14              371                3.6
  WHSC1L1    0.0154    1.886   1.129    3.151                 129             219                37.1
  SETD5      0.1644    0.481   0.151    1.531                 28              346                7.5
  PRDM8      0.3963    0.573   0.140    2.341                 15              373                3.9
  EZH2       0.0977    0.000   0.000    Inf                   8               318                2.5
  SUV420H1   0.1404    0.000   0.000    Inf                   6               360                1.6
  SETDB1     0.1916    0.000   0.000    Inf                   2               369                0.5
  EZH1       0.0528    1.783   1.026    3.096                 50              345                12.7
  PRDM15     0.0550    2.129   1.053    4.307                 26              355                6.8
  PRDM6      0.0598    2.008   1.031    3.914                 32              354                8.3
  SETD1A     0.0611    2.085   1.032    4.214                 25              351                6.6
  PRDM1      0.0788    1.512   0.959    2.383                 122             275                30.7
  SETD7      0.0805    2.162   0.989    4.727                 17              371                4.4
  KMT2B      0.0874    2.118   0.971    4.620                 16              374                4.1
  PRDM4      0.0918    2.234   0.965    5.171                 19              360                5.0
  PRDM9      0.0966    2.675   0.972    7.362                 10              364                2.7
  PRDM13     0.1008    1.473   0.932    2.327                 125             269                31.7
  SUV39H1    0.1021    2.042   0.937    4.449                 20              370                5.1
  PRDM11     0.1118    1.846   0.916    3.719                 26              357                6.8
  SMYD5      0.1304    1.855   0.884    3.892                 24              363                6.2
  SETD1B     0.1357    1.774   0.879    3.580                 28              355                7.3
  SETD8      0.1572    1.672   0.856    3.269                 31              354                8.1
  SMYD3      0.1598    2.058   0.828    5.119                 14              364                3.7
  SETD3      0.1602    1.595   0.860    2.956                 31              358                8.0
  EHMT1      0.2166    2.283   0.712    7.313                 8               345                2.3
  PRDM12     0.2324    2.215   0.690    7.111                 10              345                2.8
  SMYD4      0.2552    1.373   0.808    2.334                 67              327                17.0
  NSD1       0.2914    1.994   0.625    6.357                 10              367                2.7
  PRDM2      0.3186    1.405   0.740    2.668                 35              362                8.8
  PRDM14     0.3336    3.197   0.436    23.424                2               285                0.7
  KMT2D      0.3915    1.524   0.615    3.777                 16              372                4.1
  ASH1L      0.4391    1.635   0.513    5.211                 8               364                2.2
  PRDM16     0.4450    1.327   0.658    2.676                 29              363                7.4
  KMT2C      0.5010    0.685   0.214    2.197                 21              304                6.5
  SETD2      0.6543    1.218   0.526    2.817                 19              356                5.1
  WHSC1      0.7368    0.844   0.307    2.321                 21              362                5.5
  SETMAR     0.7739    0.865   0.314    2.382                 21              353                5.6
  PRDM5      0.7968    0.904   0.415    1.971                 36              353                9.3
  SMYD2      0.8241    1.111   0.447    2.762                 20              358                5.3
  KMT2A      0.8987    1.056   0.457    2.441                 29              348                7.7
  PRDM10     0.9515    0.965   0.303    3.077                 19              356                5.1
  MECOM      0.9671    1.025   0.318    3.305                 7               330                2.1
  KMT2E      0.9844    0.986   0.239    4.064                 7               316                2.2

###### 

Summary of univariate analysis of RFS for **methylation level of 51 HMTs** in prostate cancer.

  Gene       p-Value   HR         95% CI     
  ---------- --------- ---------- ---------- ----------
  PRDM14     0.0023    2.00E+01   2.93E+00   1.37E+02
  PRDM13     0.0181    1.17E+01   1.57E+00   8.66E+01
  PRDM6      0.0184    5.91E+01   2.28E+00   1.53E+03
  PRDM8      0.0211    1.58E+01   1.56E+00   1.60E+02
  KMT2B      0.0383    1.56E−02   3.31E−04   7.31E−01
  NSD1       0.0441    3.10E+01   1.07E+00   8.99E+02
  SETDB2     0.0572    6.91E−02   4.83E−03   9.87E−01
  SETDB1     0.0580    3.52E−05   1.11E−09   1.11E+00
  SETD4      0.0873    1.31E+13   5.38E−02   3.18E+27
  EZH2       0.1045    7.80E−10   3.21E−21   1.90E+02
  KMT2E      0.1152    1.45E+01   6.10E−01   3.45E+02
  PRDM4      0.1323    4.90E+03   1.71E−01   1.40E+08
  SUV39H1    0.1694    3.77E+01   2.58E−01   5.50E+03
  PRDM12     0.1911    1.19E+01   3.34E−01   4.23E+02
  SMYD3      0.2266    2.15E+04   1.62E−03   2.87E+11
  MECOM      0.2358    4.09E+01   1.15E−01   1.45E+04
  DOT1L      0.2610    3.25E+05   2.83E−04   3.73E+14
  SETD6      0.2710    4.95E−05   3.38E−13   7.26E+03
  SETD3      0.3030    1.56E−01   4.77E−03   5.09E+00
  PRDM9      0.3091    5.09E−01   1.39E−01   1.86E+00
  SETD5      0.3255    1.49E−01   3.32E−03   6.66E+00
  WHSC1L1    0.3297    1.86E+02   7.11E−03   4.86E+06
  PRDM1      0.3832    4.35E+00   1.70E−01   1.12E+02
  SUV420H2   0.3911    8.48E+07   1.16E−09   6.20E+24
  KMT2D      0.4038    4.02E−04   3.62E−12   4.46E+04
  SUV39H2    0.4289    6.77E+06   1.22E−10   3.77E+23
  SETD1A     0.4393    9.61E−03   6.83E−08   1.35E+03
  PRDM5      0.5427    1.69E+00   3.16E−01   9.06E+00
  SMYD2      0.5584    2.99E+01   1.02E−03   8.79E+05
  SETD7      0.5756    2.92E−04   1.06E−16   8.05E+08
  EZH1       0.6304    1.22E+01   4.84E−04   3.09E+05
  PRDM15     0.6484    6.84E−02   6.01E−07   7.78E+03
  PRDM11     0.6665    3.32E−01   2.30E−03   4.80E+01
  PRDM10     0.7125    4.99E−01   1.26E−02   1.98E+01
  SETD2      0.7127    5.25E−04   1.16E−21   2.37E+14
  SMYD5      0.7344    2.17E−01   3.15E−05   1.49E+03
  SETD8      0.7427    2.28E−03   7.04E−20   7.36E+13
  PRDM7      0.7496    5.91E−01   2.37E−02   1.48E+01
  SMYD1      0.7786    7.48E−01   1.00E−01   5.57E+00
  ASH1L      0.8598    6.00E−01   1.78E−03   2.02E+02
  SETMAR     0.8750    2.48E+00   3.02E−05   2.03E+05
  EHMT2      0.8931    1.75E−01   1.51E−12   2.02E+10
  SUV420H1   0.8952    2.14E+00   2.59E−05   1.77E+05
  WHSC1      0.9032    7.11E−01   2.96E−03   1.71E+02
  KMT2A      0.9108    2.45E+01   1.39E−23   4.30E+25
  PRDM2      0.9111    2.29E+00   1.16E−06   4.51E+06
  EHMT1      NA        NA         NA         NA
  KMT2C      NA        NA         NA         NA
  PRDM16     NA        NA         NA         NA
  SETD1B     NA        NA         NA         NA
  SMYD4      NA        NA         NA         NA

###### 

Summary of uniivariate analysis of RFS for **expression level of 51 HMTs** in prostate cancer.

  Gene       p-Value    HR      95%CI   Coef.   Wald test   
  ---------- ---------- ------- ------- ------- ----------- -------
  EZH2       0          2.897   1.755   4.78    1.064       17.31
  SETD5      3.00E-04   2.343   1.478   3.715   0.852       13.13
  WHSC1      4.00E-04   2.392   1.478   3.87    0.872       12.61
  SETD1B     0.0054     1.931   1.215   3.07    0.658       7.74
  SUV420H2   0.0054     1.93    1.214   3.067   0.657       7.74
  PRDM6      0.0066     0.526   0.331   0.836   −0.642      7.38
  PRDM15     0.0101     1.829   1.155   2.898   0.604       6.62
  KMT2D      0.0119     1.793   1.137   2.827   0.584       6.32
  SMYD1      0.0207     0.471   0.249   0.891   −0.753      5.35
  PRDM10     0.0235     1.682   1.073   2.639   0.52        5.13
  KMT2B      0.0269     1.666   1.06    2.618   0.51        4.9
  PRDM16     0.0395     0.617   0.39    0.977   −0.483      4.24
  DOT1L      0.0397     1.617   1.023   2.556   0.481       4.23
  PRDM8      0.076      0.658   0.415   1.045   −0.418      3.15
  PRDM12     0.0764     1.522   0.956   2.422   0.42        3.14
  SUV39H1    0.099      1.475   0.93    2.34    0.389       2.72
  KMT2C      0.1048     1.448   0.926   2.264   0.37        2.63
  SETD8      0.1267     0.705   0.45    1.104   −0.35       2.33
  KMT2E      0.1411     1.402   0.894   2.2     0.338       2.17
  NSD1       0.1462     1.392   0.891   2.175   0.331       2.11
  EHMT1      0.1524     1.386   0.886   2.166   0.326       2.05
  SETD3      0.1529     0.722   0.461   1.129   −0.326      2.04
  PRDM1      0.1609     1.378   0.88    2.156   0.32        1.97
  SETD4      0.1734     1.376   0.869   2.178   0.319       1.85
  PRDM11     0.2041     0.745   0.472   1.174   −0.295      1.61
  SETDB2     0.2374     1.313   0.836   2.063   0.272       1.4
  MECOM      0.2825     0.78    0.497   1.227   −0.248      1.15
  SETDB1     0.2992     1.267   0.811   1.98    0.236       1.08
  SUV39H2    0.3051     0.788   0.5     1.242   −0.238      1.05
  SETD2      0.3203     1.256   0.801   1.968   0.228       0.99
  PRDM14     0.3581     1.44    0.661   3.137   0.365       0.84
  SETD6      0.4063     1.207   0.774   1.883   0.188       0.69
  SMYD5      0.4071     1.209   0.772   1.892   0.19        0.69
  SETMAR     0.4329     0.836   0.535   1.307   −0.179      0.61
  SUV420H1   0.4691     1.179   0.755   1.841   0.165       0.52
  ASH1L      0.5269     1.156   0.738   1.811   0.145       0.4
  KMT2A      0.5758     1.136   0.727   1.775   0.127       0.31
  WHSC1L1    0.59       0.885   0.567   1.381   −0.123      0.29
  PRDM5      0.6124     0.889   0.565   1.4     −0.117      0.26
  EHMT2      0.631      1.115   0.715   1.741   0.109       0.23
  PRDM7      0.6638     0.899   0.555   1.455   −0.107      0.19
  SMYD3      0.6794     1.098   0.704   1.714   0.094       0.17
  EZH1       0.7453     0.929   0.595   1.45    −0.074      0.11
  PRDM9      0.8192     0.907   0.392   2.097   −0.098      0.05
  SMYD4      0.8539     1.043   0.665   1.637   0.042       0.03
  SMYD2      0.8758     1.036   0.664   1.617   0.035       0.02
  SETD7      0.8837     1.034   0.657   1.629   0.034       0.02
  PRDM13     0.8883     1.038   0.619   1.741   0.037       0.02
  PRDM2      0.9321     0.981   0.626   1.536   −0.019      0.01
  PRDM4      0.982      1.005   0.645   1.568   0.005       0
  SETD1A     0.9988     1       0.641   1.562   0           0

###### 

Summary of multivariate analysis of RFS for amplification of 21 HMTs in prostate cancer.

  Multivariate       Age       Pathology T       Gleason score       AR expression       EHMT1 amplification          
  ------------------ --------- ----------------- ------------------- ------------------- ---------------------------- -------
  Coefficient        −0.017    0.788             0.988               0.198               0.646                        
  Hazard ratio       0.983     2.198             2.687               1.219               1.908                        
  95%CI              Lower     0.948             1.139               1.59                0.767                        1.112
  Higher             1.019     4.241             4.538               1.938               3.274                        
  p-Value            0.35      0.0189            0.0002              0.4019              **0.0191**                   
  **Multivariate**   **Age**   **Pathology T**   **Gleason score**   **AR expression**   **EHMT2 amplification**      
  Coefficient        −0.004    0.717             0.906               0.239               0.666                        
  Hazard ratio       0.996     2.049             2.476               1.27                1.947                        
  95%CI              Lower     0.961             1.089               1.473               0.795                        0.83
  Higher             1.033     3.854             4.16                2.029               4.57                         
  p-Value            0.8407    0.0261            0.0006              0.3177              0.1257                       
  **Multivariate**   **Age**   **Pathology T**   **Gleason score**   **AR expression**   **PRDM12 amplification**     
  Coefficient        −0.007    0.676             0.921               0.325               0.665                        
  Hazard ratio       0.993     1.967             2.512               1.384               1.945                        
  95%CI              Lower     0.959             1.037               1.492               0.871                        1.125
  Higher             1.029     3.73              4.23                2.2                 3.362                        
  p-Value            0.7062    0.0383            0.0005              0.1691              **0.0172**                   
  **Multivariate**   **Age**   **Pathology T**   **Gleason score**   **AR expression**   **PRDM14 amplification**     
  Coefficient        −0.007    0.757             0.984               0.226               0.329                        
  Hazard ratio       0.993     2.131             2.675               1.254               1.39                         
  95%CI              Lower     0.959             1.136               1.61                0.797                        0.875
  Higher             1.029     3.999             4.446               1.972               2.209                        
  p-Value            0.7034    0.0184            0.0001              0.3271              0.1637                       
  **Multivariate**   **Age**   **Pathology T**   **Gleason score**   **AR expression**   **PRDM15 amplification**     
  Coefficient        −0.005    0.654             0.952               0.132               0.436                        
  Hazard ratio       0.995     1.923             2.59                1.141               1.546                        
  95%CI              Lower     0.958             1.019               1.534               0.704                        0.743
  Higher             1.033     3.629             4.372               1.849               3.22                         
  p-Value            0.7942    0.0436            0.0004              0.5931              0.2442                       
  **Multivariate**   **Age**   **Pathology T**   **Gleason score**   **AR expression**   **PRDM4 amplification**      
  Coefficient        −0.006    0.779             0.923               0.263               0.867                        
  Hazard ratio       0.994     2.179             2.517               1.301               2.379                        
  95%CI              Lower     0.959             1.164               1.502               0.801                        1.143
  Higher             1.031     4.082             4.219               2.112               4.953                        
  p-Value            0.7471    0.0149            0.0005              0.2881              **0.0205**                   
  **Multivariate**   **Age**   **Pathology T**   **Gleason score**   **AR expression**   **SETD1A amplification**     
  Coefficient        −0.015    0.872             0.893               0.073               0.391                        
  Hazard ratio       0.985     2.392             2.442               1.076               1.479                        
  95%CI              Lower     0.947             1.217               1.43                0.662                        0.722
  Higher             1.024     4.702             4.171               1.749               3.029                        
  p-Value            0.4491    0.0114            0.0011              0.7672              0.2851                       
  **Multivariate**   **Age**   **Pathology T**   **Gleason score**   **AR expression**   **SETD1B amplification**     
  Coefficient        −0.003    0.796             0.907               0.152               1.218                        
  Hazard ratio       0.997     2.216             2.477               1.164               3.381                        
  95%CI              Lower     0.961             1.179               1.467               0.711                        1.55
  Higher             1.034     4.166             4.18                1.906               7.372                        
  p-Value            0.8521    0.0135            0.0007              0.5451              **0.0022**                   
  **Multivariate**   **Age**   **Pathology T**   **Gleason score**   **AR expression**   **SETD8 Amplification**      
  Coefficient        0         0.8               0.898               0.2                 0.97                         
  Hazard ratio       1         2.226             2.456               1.221               2.638                        
  95%CI              Lower     0.964             1.182               1.453               0.747                        1.101
  Higher             1.038     4.191             4.152               1.996               6.323                        
  p-Value            0.9897    0.0132            0.0008              0.4256              **0.0296**                   
  **Multivariate**   **Age**   **Pathology T**   **Gleason score**   **AR expression**   **SETDB1 amplification**     
  Coefficient        −0.009    0.812             0.941               0.158               0.701                        
  Hazard ratio       0.991     2.253             2.563               1.171               2.016                        
  95%CI              Lower     0.957             1.209               1.559               0.744                        1.062
  Higher             1.027     4.2               4.214               1.842               3.826                        
  p-Value            0.6255    0.0106            0.0002              0.4956              **0.0319**                   
  **Multivariate**   **Age**   **Pathology T**   **Gleason score**   **AR expression**   **SMYD1 amplification**      
  Coefficient        −0.004    0.788             0.906               0.15                1.423                        
  Hazard ratio       0.996     2.198             2.475               1.162               4.149                        
  95%CI              Lower     0.959             1.139               1.443               0.716                        1.844
  Higher             1.034     4.243             4.244               1.885               9.336                        
  p-Value            0.8369    0.0189            0.001               0.5434              **0.0006**                   
  **Multivariate**   **Age**   **Pathology T**   **Gleason score**   **AR expression**   **SMYD2 amplification**      
  Coefficient        0         0.798             0.955               0.181               0.77                         
  Hazard ratio       1         2.221             2.6                 1.198               2.159                        
  95%CI              Lower     0.965             1.16                1.556               0.751                        1.026
  Higher             1.037     4.253             4.343               1.91                4.546                        
  p-Value            0.9835    0.0161            0.0003              0.4483              **0.0426**                   
  **Multivariate**   **Age**   **Pathology T**   **Gleason score**   **AR expression**   **SMYD5 Amplification**      
  Coefficient        0.004     0.745             0.929               0.163               1.274                        
  Hazard ratio       1.004     2.106             2.532               1.177               3.574                        
  95%CI              Lower     0.967             1.119               1.484               0.729                        1.595
  Higher             1.042     3.966             4.32                1.901               8.01                         
  p-Value            0.8462    0.0211            0.0007              0.5045              **0.002**                    
  **Multivariate**   **Age**   **Pathology T**   **Gleason score**   **AR expression**   **SUV420H1 amplification**   
  Coefficient        −0.006    0.835             0.897               0.155               0.394                        
  Hazard ratio       0.994     2.304             2.452               1.168               1.483                        
  95%CI              Lower     0.96              1.237               1.48                0.742                        0.809
  Higher             1.03      4.289             4.064               1.838               2.718                        
  p-Value            0.7365    0.0085            0.0005              0.5016              0.2028                       
  **Multivariate**   **Age**   **Pathology T**   **Gleason score**   **AR expression**   **SUV420H2 amplification**   
  Coefficient        −0.014    0.885             0.927               0.072               0.422                        
  Hazard ratio       0.986     2.422             2.528               1.075               1.524                        
  95%CI              Lower     0.949             1.263               1.51                0.664                        0.673
  Higher             1.025     4.642             4.231               1.741               3.455                        
  p-Value            0.4852    0.0077            0.0004              0.7691              0.3126                       
  **Multivariate**   **Age**   **Pathology T**   **Gleason score**   **AR expression**   **WHSC1 amplification**      
  Coefficient        −0.014    0.786             1.051               0.152               0.439                        
  Hazard ratio       0.986     2.194             2.86                1.165               1.551                        
  95%CI              Lower     0.951             1.142               1.702               0.733                        0.732
  Higher             1.022     4.218             4.806               1.851               3.286                        
  p-Value            0.4366    0.0184            0.0001              0.5191              0.2522                       
  **Multivariate**   **Age**   **Pathology T**   **Gleason score**   **AR expression**   **WHSC1L1 amplification**    
  Coefficient        0.001     0.486             1.027               0.21                0.565                        
  Hazard ratio       1.001     1.627             2.792               1.233               1.76                         
  95%CI              Lower     0.956             0.709               1.378               0.686                        0.946
  Higher             1.049     3.732             5.657               2.216               3.272                        
  p-Value            0.95      0.251             0.0044              0.4836              0.0742                       

###### 

Summary of multivariate analysis of RFS for deletion of 10 HMTs in prostate cancer.

  Multivariate       Age       Pathology T       Gleason score       AR expression       DOT1L deletion          
  ------------------ --------- ----------------- ------------------- ------------------- ----------------------- -------
  Coefficient        −0.003    0.742             0.971               0.304               0.441                   
  Hazard ratio       0.997     2.101             2.64                1.356               1.554                   
  95%CI              Lower     0.962             1.118               1.585               0.847                   0.815
  Higher             1.033     3.945             4.397               2.17                2.963                   
  p-Value            0.8719    0.021             0.0002              0.2053              0.1802                  
  **Multivariate**   **Age**   **Pathology T**   **Gleason score**   **AR expression**   **EHMT2 deletion**      
  Coefficient        0.004     0.775             0.951               0.176               0.992                   
  Hazard ratio       1.004     2.17              2.588               1.193               2.695                   
  95%CI              Lower     0.968             1.156               1.548               0.743                   1.135
  Higher             1.042     4.074             4.327               1.916               6.398                   
  p-Value            0.81      0.016             0.0003              0.4662              **0.0246**              
  **Multivariate**   **Age**   **Pathology T**   **Gleason score**   **AR expression**   **PRDM7 deletion**      
  Coefficient        0.003     0.796             0.947               0.196               0.333                   
  Hazard ratio       1.003     2.217             2.577               1.216               1.395                   
  95%CI              Lower     0.969             1.19                1.563               0.773                   0.881
  Higher             1.039     4.133             4.25                1.914               2.208                   
  p-Value            0.8706    0.0122            0.0002              0.397               0.1559                  
  **Multivariate**   **Age**   **Pathology T**   **Gleason score**   **AR expression**   **SETD4 deletion**      
  Coefficient        −0.006    0.733             0.991               0.177               1.097                   
  Hazard ratio       0.994     2.081             2.694               1.194               2.996                   
  95%CI              Lower     0.959             1.107               1.598               0.738                   1.336
  Higher             1.031     3.91              4.545               1.932               6.716                   
  p-Value            0.7515    0.0229            0.0002              0.4706              **0.0077**              
  **Multivariate**   **Age**   **Pathology T**   **Gleason score**   **AR expression**   **SETD6 deletion**      
  Coefficient        0         0.762             0.911               0.24                0.491                   
  Hazard ratio       1         2.143             2.486               1.271               1.634                   
  95%CI              Lower     0.966             1.146               1.486               0.805                   1.018
  Higher             1.035     4.006             4.159               2.008               2.622                   
  p-Value            0.9999    0.017             0.0005              0.3036              **0.042**               
  **Multivariate**   **Age**   **Pathology T**   **Gleason score**   **AR expression**   **SETDB2 deletion**     
  Coefficient        −0.007    0.835             0.928               0.125               0.322                   
  Hazard ratio       0.993     2.305             2.531               1.133               1.38                    
  95%CI              Lower     0.96              1.237               1.529               0.721                   0.868
  Higher             1.028     4.298             4.189               1.782               2.195                   
  p-Value            0.6953    0.0086            0.0003              0.5873              0.1739                  
  **Multivariate**   **Age**   **Pathology T**   **Gleason score**   **AR expression**   **SMYD1 deletion**      
  Coefficient        0         0.755             0.96                0.309               0.998                   
  Hazard ratio       1         2.128             2.612               1.362               2.714                   
  95%CI              Lower     0.964             1.135               1.558               0.848                   1.329
  Higher             1.038     3.99              4.378               2.189               5.543                   
  p-Value            0.9902    0.0185            0.0003              0.2012              **0.0061**              
  **Multivariate**   **Age**   **Pathology T**   **Gleason score**   **AR expression**   **SUV39H2 deletion**    
  Coefficient        −0.013    0.774             0.976               0.187               0.755                   
  Hazard ratio       0.987     2.169             2.655               1.205               2.129                   
  95%CI              Lower     0.953             1.15                1.588               0.761                   1.199
  Higher             1.022     4.092             4.437               1.909               3.778                   
  p-Value            0.4618    0.0168            0.0002              0.4265              **0.0099**              
  **Multivariate**   **Age**   **Pathology T**   **Gleason score**   **AR expression**   **SUV420H2 deletion**   
  Coefficient        0         0.77              0.89                0.289               0.553                   
  Hazard ratio       1         2.16              2.435               1.335               1.738                   
  95%CI              Lower     0.964             1.147               1.443               0.831                   0.808
  Higher             1.037     4.071             4.108               2.144               3.736                   
  p-Value            0.9946    0.0172            0.0009              0.232               0.1572                  
  **Multivariate**   **Age**   **Pathology T**   **Gleason score**   **AR expression**   **WHSC1L1 deletion**    
  Coefficient        −0.001    0.681             1.184               0.121               0.677                   
  Hazard ratio       0.999     1.976             3.267               1.129               1.968                   
  95%CI              Lower     0.959             1.028               1.867               0.671                   1.173
  Higher             1.04      3.8               5.716               1.899               3.303                   
  p-Value            0.9534    0.0411            0                   0.6489              **0.0103**              

###### 

Summary of multivariate analysis of RFS for higher promotor methylation of 6 HMTs in prostate cancer.

  Multivariate       Age       Pathology T       Gleason score       AR expression       PRDM14 high_meth       
  ------------------ --------- ----------------- ------------------- ------------------- ---------------------- -------
  Coefficient        −0.009    0.785             0.916               0.188               0.32                   
  Hazard ratio       0.991     2.193             2.498               1.207               1.377                  
  95%CI              Lower     0.957             1.174               1.508               0.769                  0.823
  Higher             1.027     4.095             4.139               1.894               2.303                  
  p-Value            0.6314    0.0137            0.0004              0.4131              0.223                  
  **Multivariate**   **Age**   **Pathology T**   **Gleason score**   **AR expression**   **PRDM13 high_meth**   
  Coefficient        −0.006    0.791             0.971               0.171               0.317                  
  Hazard ratio       0.994     2.206             2.641               1.187               1.373                  
  95%CI              Lower     0.96              1.182               1.608               0.755                  0.86
  Higher             1.029     4.119             4.338               1.864               2.19                   
  p-Value            0.7279    0.013             0.0001              0.4581              0.1839                 
  **Multivariate**   **Age**   **Pathology T**   **Gleason score**   **AR expression**   **PRDM6 high_meth**    
  Coefficient        −0.004    0.816             0.967               0.191               0.079                  
  Hazard ratio       0.996     2.262             2.631               1.211               1.082                  
  95%CI              Lower     0.962             1.208               1.594               0.771                  0.675
  Higher             1.031     4.235             4.341               1.901               1.734                  
  p-Value            0.8298    0.0108            0.0002              0.4059              0.7441                 
  **Multivariate**   **Age**   **Pathology T**   **Gleason score**   **AR expression**   **PRDM8 high_meth**    
  Coefficient        −0.004    0.826             0.933               0.184               0.324                  
  Hazard ratio       0.996     2.285             2.542               1.201               1.383                  
  95%CI              Lower     0.963             1.227               1.542               0.766                  0.869
  Higher             1.031     4.257             4.189               1.883               2.199                  
  p-Value            0.8314    0.0092            0.0003              0.4236              0.1712                 
  **Multivariate**   **Age**   **Pathology T**   **Gleason score**   **AR expression**   **KMT2B high_meth**    
  Coefficient        −0.003    0.86              0.897               0.229               −0.417                 
  Hazard ratio       0.997     2.363             2.452               1.257               0.659                  
  95%CI              Lower     0.963             1.274               1.486               0.8                    0.409
  Higher             1.033     4.382             4.045               1.975               1.061                  
  p-Value            0.8776    0.0064            0.0004              0.3215              0.086                  
  **Multivariate**   **Age**   **Pathology T**   **Gleason score**   **AR expression**   **NSD1 High_meth**     
  Coefficient        −0.006    0.852             0.889               0.161               0.547                  
  Hazard ratio       0.994     2.345             2.432               1.175               1.728                  
  95%CI              Lower     0.961             1.26                1.476               0.749                  1.06
  Higher             1.028     4.364             4.009               1.843               2.818                  
  p-Value            0.7268    0.0071            0.0005              0.4839              **0.0284**             

###### 

Summary of multivariate analysis of RFS for higher mRNA level of 16 HMTs in prostate cancer.

  Multivariate       Age       Pathology T       Gleason score       AR expression       DOT1L high_exp          
  ------------------ --------- ----------------- ------------------- ------------------- ----------------------- -------
  Coefficient        −0.004    0.854             0.916               0.163               0.254                   
  Hazard ratio       0.996     2.35              2.5                 1.177               1.289                   
  95%CI              Lower     0.962             1.26                1.504               0.747                   0.802
  Higher             1.032     4.382             4.157               1.855               2.071                   
  p-Value            0.8373    0.0072            0.0004              0.4813              0.2941                  
  **Multivariate**   **Age**   **Pathology T**   **Gleason score**   **AR expression**   **EZH2 high_exp**       
  Coefficient        −0.006    0.858             0.731               0.185               0.736                   
  Hazard ratio       0.994     2.357             2.076               1.203               2.088                   
  95%CI              Lower     0.961             1.263               1.23                0.768                   1.23
  Higher             1.028     4.4               3.506               1.887               3.544                   
  p-Value            0.7334    0.0071            0.0063              0.4195              **0.0064**              
  **Multivariate**   **Age**   **Pathology T**   **Gleason score**   **AR expression**   **KMT2B high_exp**      
  Coefficient        −0.004    0.877             0.923               −0.026              0.387                   
  Hazard ratio       0.996     2.403             2.516               0.975               1.472                   
  95%CI              Lower     0.962             1.288               1.526               0.563                   0.839
  Higher             1.031     4.484             4.149               1.688               2.584                   
  p-Value            0.8266    0.0059            0.0003              0.9268              0.1781                  
  **Multivariate**   **Age**   **Pathology T**   **Gleason score**   **AR expression**   **KMT2D high_exp**      
  Coefficient        −0.004    0.857             0.906               0.087               0.333                   
  Hazard ratio       0.996     2.357             2.474               1.091               1.396                   
  95%CI              Lower     0.962             1.264               1.492               0.677                   0.851
  Higher             1.031     4.393             4.102               1.758               2.289                   
  p-Value            0.8135    0.007             0.0004              0.721               0.1865                  
  **Multivariate**   **Age**   **Pathology T**   **Gleason score**   **AR expression**   **PRDM10 high_exp**     
  Coefficient        −0.003    0.829             0.94                0.054               0.266                   
  Hazard ratio       0.997     2.291             2.56                1.055               1.304                   
  95%CI              Lower     0.963             1.23                1.551               0.617                   0.755
  Higher             1.033     4.267             4.227               1.804               2.255                   
  p-Value            0.878     0.009             0.0002              0.8443              0.3412                  
  **Multivariate**   **Age**   **Pathology T**   **Gleason score**   **AR expression**   **PRDM12 high_exp**     
  Coefficient        −0.005    0.841             0.923               0.231               0.224                   
  Hazard ratio       0.995     2.319             2.517               1.26                1.251                   
  95%CI              Lower     0.962             1.245               1.512               0.799                   0.773
  Higher             1.03      4.322             4.188               1.988               2.024                   
  p-Value            0.7926    0.0081            0.0004              0.3195              0.362                   
  **Multivariate**   **Age**   **Pathology T**   **Gleason score**   **AR expression**   **PRDM15 high_exp**     
  Coefficient        −0.003    0.856             0.909               0.153               0.448                   
  Hazard ratio       0.997     2.354             2.483               1.165               1.566                   
  95%CI              Lower     0.964             1.264               1.507               0.742                   0.981
  Higher             1.033     4.383             4.092               1.83                2.5                     
  p-Value            0.8865    0.007             0.0004              0.5069              0.0604                  
  **Multivariate**   **Age**   **Pathology T**   **Gleason score**   **AR expression**   **PRDM16 high_exp**     
  Coefficient        −0.006    0.898             0.948               0.175               −0.514                  
  Hazard ratio       0.994     2.454             2.581               1.191               0.598                   
  95%CI              Lower     0.96              1.315               1.571               0.759                   0.377
  Higher             1.029     4.579             4.24                1.87                0.949                   
  p-Value            0.747     0.0048            0.0002              0.4462              **0.0293**              
  **Multivariate**   **Age**   **Pathology T**   **Gleason score**   **AR expression**   **PRDM6 high_exp**      
  Coefficient        −0.003    0.851             0.897               0.208               −0.506                  
  Hazard ratio       0.997     2.343             2.452               1.231               0.603                   
  95%CI              Lower     0.963             1.259               1.486               0.785                   0.377
  Higher             1.032     4.36              4.046               1.931               0.964                   
  p-Value            0.8603    0.0072            0.0004              0.366               **0.0345**              
  **Multivariate**   **Age**   **Pathology T**   **Gleason score**   **AR expression**   **PRDM8 high_exp**      
  Coefficient        −0.005    0.857             0.916               0.208               −0.284                  
  Hazard ratio       0.995     2.356             2.499               1.231               0.753                   
  95%CI              Lower     0.962             1.261               1.504               0.785                   0.47
  Higher             1.03      4.401             4.155               1.93                1.206                   
  p-Value            0.7952    0.0072            0.0004              0.3658              0.2375                  
  **Multivariate**   **Age**   **Pathology T**   **Gleason score**   **AR expression**   **SETD1B high_exp**     
  Coefficient        −0.008    0.861             0.903               0.059               0.453                   
  Hazard ratio       0.992     2.365             2.468               1.06                1.573                   
  95%CI              Lower     0.958             1.271               1.496               0.661                   0.957
  Higher             1.028     4.401             4.071               1.701               2.584                   
  p-Value            0.6715    0.0066            0.0004              0.8076              0.0738                  
  **Multivariate**   **Age**   **Pathology T**   **Gleason score**   **AR expression**   **SETD5 high_exp**      
  Coefficient        −0.005    0.784             0.903               0.033               0.584                   
  Hazard ratio       0.995     2.191             2.466               1.033               1.794                   
  95%CI              Lower     0.961             1.176               1.496               0.646                   1.1
  Higher             1.031     4.082             4.067               1.651               2.926                   
  p-Value            0.7935    0.0135            0.0004              0.8915              **0.0193**              
  **Multivariate**   **Age**   **Pathology T**   **Gleason score**   **AR expression**   **SMYD1 high_exp**      
  Coefficient        −0.009    0.862             1.002               0.191               −0.819                  
  Hazard ratio       0.991     2.369             2.723               1.21                0.441                   
  95%CI              Lower     0.957             1.269               1.662               0.772                   0.232
  Higher             1.027     4.423             4.461               1.896               0.838                   
  p-Value            0.623     0.0068            0.0001              0.405               **0.0124**              
  **Multivariate**   **Age**   **Pathology T**   **Gleason score**   **AR expression**   **SUV39H1 high_exp**    
  Coefficient        −0.007    0.86              0.925               0.22                0.329                   
  Hazard ratio       0.993     2.363             2.521               1.246               1.39                    
  95%CI              Lower     0.958             1.267               1.525               0.792                   0.866
  Higher             1.028     4.407             4.167               1.958               2.23                    
  p-Value            0.6758    0.0068            0.0003              0.3412              0.1728                  
  **Multivariate**   **Age**   **Pathology T**   **Gleason score**   **AR expression**   **SUV420H2 high_exp**   
  Coefficient        −0.009    0.852             0.847               0.382               0.586                   
  Hazard ratio       0.991     2.344             2.334               1.465               1.796                   
  95%CI              Lower     0.957             1.257               1.402               0.909                   1.087
  Higher             1.027     4.37              3.884               2.361               2.966                   
  p-Value            0.6247    0.0073            0.0011              0.1165              **0.0222**              
  **Multivariate**   **Age**   **Pathology T**   **Gleason score**   **AR expression**   **WHSC1 high_exp**      
  Coefficient        −0.005    0.815             0.831               0.146               0.429                   
  Hazard ratio       0.995     2.259             2.297               1.157               1.535                   
  95%CI              Lower     0.961             1.21                1.357               0.735                   0.913
  Higher             1.03      4.217             3.888               1.821               2.581                   
  p-Value            0.7789    0.0105            0.002               0.5276              0.1057                  
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![Box plots showing histone lysine methyltransferase (HKMT) mRNA levels in 52 matched prostate cancer tissues (grey) and adjacent normal tissues (brown). Paired t-test was performed to compare the different expression profiles between tumor and adjacent normal tissues. Statistical significance is shown as the p-values by different grayscales of the lower color bars (p\>0.05 are specifically shown by \* inside the sub-boxes). There was reduced mRNA expression of several genes, including PRDM7, PRDM9, PRDM13, PRDM14, and SMYD1.](medscimonit-25-193-g001){#f1-medscimonit-25-193}

![Expression profiles of altered copy numbers of histone lysine methyltransferase (HKMT) in samples of prostate cancer according to Gleason scores. (**A**) The pheatmap package in R shows that increasing copy number alteration (CNA) events of 51 histone methyltransferases (HMTs) in prostate cancer samples, with a Gleason score of 6 to 9, were significantly associated with the clinical stage. (**B**) A histogram shows the effect on HMT expression levels due to changes in gene copy numbers. The y-axis represents the proportion of genes expressed (higher or lower) associated with different types of copy number alterations. (**C**) A histogram shows that the average CNA events of HMTs in each sample are incrementally increased with an increase in Gleason score.](medscimonit-25-193-g002){#f2-medscimonit-25-193}

![DNA methylation profiles of histone methyltransferases (HMTs) in prostate cancer (adenocarcinoma). (**A**) The pheatmap package in R showed different promoter methylation levels in 50 paired tumor tissues and corresponding adjacent tissues. Promoter CpG sites of most histone methyltransferases (HMTs) are expected at low methylation level and the difference between tumor and normal tissues are unexpected plain. PRDM5 and PRDM8 were indicated by triangle because their mRNA levels are both 1.2-fold-change from normal to tumor tissues and have a high correlation coefficient to the corresponding gene expression level. (**B, C**) Scatter diagrams showed the relationship between gene expression and its promoter methylation state (β value) in 399 prostate cancers. Survival analysis show samples with lower PRDM5 promoter methylation as well as PRDM8 have a better prognosis in some extent than higher ones. (**C**) Two CpG sites in the PRDM8 promoter which are both 1.2-fold-change between normal and tumor tissues have an increased correlation with PRDM8 mRNA levels compared with other CpG sites.](medscimonit-25-193-g003){#f3-medscimonit-25-193}

![The KMT2C and KMT2D gene mutation spectrum in prostate carcinoma. (**A**) Bar graphs show the top five mutated histone methyltransferases (HMTs). (**B**) The frequency of each mutation type for KMT2C and KMT2D from 429 primary prostate adenocarcinomas. The data were obtained from The Cancer Genome Atlas (TCGA) database. (**C**) The images show protein domains and the positions of specific mutations of the KMT2C and KMT2D genes. A green dot indicates a missense mutation. The black dot indicates a truncating mutation include nonsense mutation, frameshift deletion, insertion, or splice. A brown dot indicates an in-frame insertion or deletion mutation. (**D**) Mutual exclusivity relationship for copy number alterations and mutation of the top five mutated HMTs in prostate cancers.](medscimonit-25-193-g004){#f4-medscimonit-25-193}

![Co-expression of histone methyltransferases (HMTs) and androgen receptors. The pheatmap package in R shows that several histone methyltransferases (HMTs) (ASH1L, SETD2, KMT2B, NSD1, KMT2C, SETD7, KMT2E, KMT2A, PRDM10, SETD5, PRDM2, PRDM4, and WHSC1L1) were significantly clustering in the higher androgen receptor (AR) expression cluster.](medscimonit-25-193-g005){#f5-medscimonit-25-193}

![Genetic alterations of histone methyltransferases (HMTs) are associated with recurrence-free survival (RFS) of patients with prostate carcinoma. (**A**) The 28 genetic alterations (including mutation, amplification, deletion, increased gene expression, and methylation) of histone methyltransferases (HMTs) are shown by forest plot to demonstrate their impact on clinical survival, showing the hazard ratio (HR), 95% confidence interval (CI) and p-value (Wald test). (**B**) Critical HMT genes (EZH2, NSD1, RPDM12, SETD5, SETD6, SMYD1, and WHSC1L1) were analyzed using the mRNA score, copy number alterations (CNAs) and promoter methylation associated survival, CNA frequencies, differential expression and methylation, correlation of CNA, androgen receptor (AR) expression, and Gleason score with HMT expression. (**C**) Kaplan-Meier plot of the recurrence-free survival (RFS) show that two typical HMT genes (EZH2 and SETD5) have the same clinic outcome of amplification and increased expression or deletion and reduced expression.](medscimonit-25-193-g006){#f6-medscimonit-25-193}

![The histone methyltransferase (HMT) predictor-score analysis of 399 prostate cancer patients in the Cancer Genome Atlas (TCGA) cohort. (**A**) Expression profile of four histone methyltransferases (HMTs) in high-risk and low-risk patients. (**B**) Kaplan-Meier plot shows the recurrence-free survival (RFS) in high-risk and low-risk patients. (**C**) A time-dependent area under the receiver operating characteristics (AUROC) curve was used to assess the prognostic value of the four HMT gene prognostic signature (EZH2, SETD5, SMYD1, and SUV420H2). The AUC for the four HMT gene prognostic signature model at one, three, and five years were 0.717, 0.690, and 0.720, respectively via cross-validation (purple).](medscimonit-25-193-g007){#f7-medscimonit-25-193}

![SETD5 gene knockdown reduced cell growth and migration in the 22Rv1 human prostate carcinoma cell line *in vitro*. (**A**) Differential expression of the SETD5 gene in primary prostate cancer (pPCa) and metastatic prostate cancer (mPCa) tissue samples. (**B**) The 22Rv1 human prostate carcinoma cells were stably transfected with lentivirus to knockdown the SETD5 gene. Real-time quantitative reverse transcription polymerase chain reaction (qRT-PCR) detected the SETD5 gene expression level. (**C**) The stable transfection of the 22Rv1 cells underwent a colony formation assay. (**D**) The MTS cell proliferation assay was performed in stably transfected 22Rv1 cells. (**E**) A transwell assay was used to evaluate the migration capacity of stably transfected 22Rv1 cells.](medscimonit-25-193-g008){#f8-medscimonit-25-193}

###### 

Frequency of HMTs copy number alterations and mutations (%).

  Gene       Location   Amp    Gain    Diploid   Hetloss   Homdel   Mutation
  ---------- ---------- ------ ------- --------- --------- -------- ----------
  SETDB2     13q14.2    0.00   0.81    54.88     27.64     16.67    0.24
  PRDM1      6q21       0.00   0.41    67.07     18.70     13.82    0.00
  PRDM13     6q16.2     0.00   1.22    66.06     19.11     13.62    0.00
  PRDM7      16q24.3    0.20   1.02    60.57     29.88     8.33     0.47
  WHSC1L1    8p11.23    2.64   11.38   52.44     27.44     6.10     0.71
  PRDM5      4q27       0.00   2.85    87.60     6.30      3.25     0.24
  EZH1       17q21.2    0.00   1.02    86.18     10.16     2.64     0.24
  SETD5      3p25.3     0.20   6.91    85.77     4.47      2.64     0.24
  SETD6      16q21      0.20   1.22    73.98     21.95     2.64     0.00
  PRDM11     11p11.2    0.20   4.47    88.82     4.27      2.24     0.00
  PRDM6      5q23.2     0.20   2.64    87.20     8.13      1.83     0.00
  KMT2A      11q23.3    0.41   5.89    85.77     6.30      1.63     1.18
  PRDM15     21q22.3    0.00   4.67    87.40     6.50      1.42     0.24
  SETD1B     12q24.31   0.81   4.88    87.20     5.69      1.42     0.00
  SETD2      3p21.31    0.00   7.11    87.80     3.66      1.42     0.94
  SETMAR     3p26.1     0.20   7.32    86.79     4.27      1.42     0.00
  SMYD2      1q32.3     0.00   6.30    88.41     3.86      1.42     0.24
  KMT2C      7q36.1     0.41   18.70   75.41     4.27      1.22     5.41
  SETD3      14q32.2    0.41   2.64    89.02     6.71      1.22     0.00
  PRDM10     11q24.3    0.81   6.10    87.60     4.47      1.02     0.24
  SMYD4      17p13.3    0.00   1.42    80.08     17.48     1.02     0.00
  PRDM2      1p36.21    0.20   0.61    89.23     9.15      0.81     0.47
  SETD8      12q24.31   0.61   4.27    87.40     6.91      0.81     0.00
  SMYD5      2p13.2     0.41   2.64    90.24     5.89      0.81     0.00
  DOT1L      19p13.3    0.20   1.22    90.24     7.72      0.61     0.71
  PRDM9      5p14.2     0.61   6.30    89.43     3.05      0.61     0.71
  SETD1A     16p11.2    0.41   6.10    86.79     6.10      0.61     0.47
  SMYD3      1q44       0.41   5.89    90.04     3.05      0.61     0.00
  SUV39H2    10p13      0.41   3.46    86.59     8.94      0.61     0.00
  SUV420H1   11q13.2    2.44   7.32    89.02     0.61      0.61     0.24
  WHSC1      4p16.3     1.02   2.85    89.43     6.10      0.61     0.24
  ASH1L      1q22       1.42   6.10    90.04     2.03      0.41     1.88
  EHMT2      6p21.31    0.20   3.66    91.46     4.27      0.41     0.24
  EZH2       7q36.1     0.41   18.70   79.07     1.42      0.41     0.24
  KMT2B      19q13.12   0.41   2.03    92.89     4.27      0.41     0.47
  KMT2E      7q22.3     0.81   18.70   78.25     1.83      0.41     0.94
  PRDM16     1p36.32    0.41   1.63    89.43     8.13      0.41     0.24
  PRDM8      4q21.21    0.41   2.64    92.89     3.66      0.41     0.71
  SETD4      21q22.12   0.00   4.67    89.23     5.69      0.41     0.00
  SETD7      4q31.1     0.00   3.25    91.26     5.08      0.41     0.00
  SMYD1      2p11.2     0.41   2.24    91.46     5.49      0.41     0.00
  PRDM12     9q34.12    1.22   10.57   85.37     2.64      0.20     0.47
  PRDM4      12q23.3    1.02   5.28    88.82     4.67      0.20     0.00
  EHMT1      9q34.3     1.42   10.57   85.37     2.64      0.00     0.00
  KMT2D      12q13.12   0.20   3.25    91.87     4.67      0.00     4.94
  MECOM      3q26.2     3.66   13.62   80.69     2.03      0.00     1.18
  NSD1       5q35.2     0.81   4.27    91.67     3.25      0.00     0.47
  PRDM14     8q13.3     6.10   24.80   68.29     0.81      0.00     0.47
  SETDB1     1q21.3     1.42   6.71    91.26     0.61      0.00     0.47
  SUV39H1    Xp11.23    1.02   2.64    90.85     5.49      0.00     0.00
  SUV420H2   19q13.42   0.41   4.07    91.46     4.07      0.00     0.24

Amp -- high-level amplification; Gain -- low-level gain; Hetless -- heterozygous deletion; Homdel -- homozygous deletion. Genes were ranked based on the frequency of Homdel.

###### 

Associations between HMTs expression and CNAs or methylation state.

  Gene       CNA/mRNA Correlation   Methylation/mRNA Correlation                              
  ---------- ---------------------- ------------------------------ -------- -------- -------- --------
  WHSC1L1    0.577                  0.577                          0.460    −0.005   0.026    −0.004
  SETDB2     0.555                  0.535                          0.435    0.122    0.183    0.083
  SETD6      0.499                  0.530                          0.407    −0.232   −0.230   −0.157
  SMYD4      0.400                  0.410                          0.325    NA       NA       NA
  EZH2       0.347                  0.363                          0.283    −0.232   −0.197   −0.160
  SETDB1     0.325                  0.411                          0.265    −0.179   −0.213   −0.119
  SETD8      0.310                  0.338                          0.251    0.015    −0.013   0.011
  SUV39H2    0.297                  0.309                          0.240    −0.043   −0.071   −0.029
  SETD3      0.294                  0.436                          0.240    −0.068   −0.091   −0.045
  EZH1       0.293                  0.359                          0.236    −0.089   −0.094   −0.059
  EHMT1      0.280                  0.355                          0.228    NA       NA       NA
  SUV420H1   0.277                  0.462                          0.226    −0.164   −0.160   −0.111
  PRDM4      0.275                  0.339                          0.223    −0.024   0.033    −0.017
  SETD4      0.265                  0.302                          0.216    0.305    0.259    0.205
  SETD5      0.243                  0.211                          0.196    −0.118   −0.078   −0.078
  KMT2C      0.243                  0.283                          0.195    NA       NA       NA
  SMYD5      0.241                  0.246                          0.196    −0.116   −0.101   −0.081
  PRDM13     0.237                  0.174                          0.216    0.346    0.327    0.266
  PRDM12     0.217                  0.205                          0.176    0.356    0.356    0.244
  SETD2      0.212                  0.176                          0.172    −0.161   −0.127   −0.112
  PRDM2      0.209                  0.216                          0.171    −0.323   −0.360   −0.219
  PRDM15     0.207                  0.238                          0.168    −0.087   −0.069   −0.058
  SETMAR     0.196                  0.229                          0.158    −0.041   −0.053   −0.028
  KMT2A      0.193                  0.209                          0.156    0.210    0.247    0.139
  SMYD3      0.189                  0.208                          0.153    0.234    0.189    0.160
  WHSC1      0.174                  0.270                          0.140    −0.133   −0.168   −0.088
  PRDM10     0.170                  0.191                          0.138    −0.093   −0.130   −0.064
  SETD1A     0.165                  0.200                          0.132    −0.071   −0.082   −0.046
  SETD7      0.164                  0.200                          0.132    0.223    0.224    0.150
  SETD1B     0.164                  0.139                          0.133    NA       NA       NA
  KMT2E      0.160                  0.169                          0.129    0.129    0.048    0.087
  SMYD2      0.158                  0.252                          0.129    −0.140   −0.215   −0.093
  PRDM5      0.155                  0.162                          0.125    −0.523   −0.551   −0.365
  PRDM6      0.154                  0.157                          0.124    −0.262   −0.265   −0.175
  PRDM14     0.150                  0.132                          0.143    0.046    0.056    0.036
  ASH1L      0.149                  0.145                          0.121    −0.298   −0.130   −0.205
  PRDM11     0.142                  0.164                          0.114    0.055    0.054    0.035
  NSD1       0.127                  0.141                          0.103    0.029    0.040    0.019
  DOT1L      0.126                  0.156                          0.103    −0.053   −0.052   −0.034
  PRDM9      0.122                  0.055                          0.118    −0.121   −0.013   −0.098
  EHMT2      0.116                  0.160                          0.094    −0.128   −0.110   −0.085
  SUV420H2   0.074                  0.100                          0.060    −0.050   −0.019   −0.032
  KMT2B      0.072                  0.055                          0.058    0.052    0.028    0.034
  KMT2D      0.059                  0.050                          0.048    0.030    0.025    0.021
  PRDM16     0.058                  0.121                          0.047    NA       NA       NA
  PRDM7      0.056                  0.035                          0.050    0.050    0.037    0.036
  MECOM      0.048                  0.059                          0.038    −0.163   −0.139   −0.113
  PRDM1      0.034                  0.061                          0.028    0.002    −0.080   0.003
  SMYD1      0.006                  0.030                          0.006    0.007    −0.041   0.005
  PRDM8      −0.011                 −0.044                         −0.009   −0.529   −0.551   −0.372
  SUV39H1    −0.050                 −0.014                         −0.040   0.007    0.049    0.005

Genes were ranked based on the Spearman correlation coefficient. Significantly associated HMTs between gene expression with CNAs or methylation were highlighted.

###### 

Summary of PRDM5 CpG sites.

  CpG ID       Genetic location    Epigenetic location   β \>0.3 in tumor(%)   β \<0.1 in normal(%)   PRDM5 mRNA level in 399 PCa samples           
  ------------ ------------------- --------------------- --------------------- ---------------------- ------------------------------------- ------- ----------
  cg07070341   TSS200              Island                16                    94                     4.418                                 5.461   1.34E-14
  cg18181323   TSS200              Island                8                     98                     3.996                                 5.418   2.34E-08
  cg19294653   TSS200              Island                8                     98                     4.043                                 5.444   3.55E-11
  cg22135105   TSS200              Island                22                    98                     4.438                                 5.506   8.41E-19
  cg11171429   TSS1500             S_Shore               20                    94                     4.358                                 5.542   2.31E-18
  cg13155001   1^st^ Exon; 5′UTR   Island                10                    100                    4.661                                 5.201   6.39E-03
  cg06329345   TSS1500             S_Shore               30                    88                     NA                                            
  cg10416963   TSS1500             S_Shore               78                    4                      NA                                            

Methylation level of CpG sites of PRDM5 in 50 paired tumor and adjacent tissues were listed. Average PRDM5 mRNA level in the two groups (β \>0.3 and β \<0.1) were calculated and T.test was used to value the significance of difference.

###### 

Association between SETD5 expression and clinical characteristics in prostate cancer from TCGA Data portal.

  Characteristics         Total (n=399)   SETD5 expression   p Value   
  ----------------------- --------------- ------------------ --------- ----------------------------------------------------------
  Age (years)                                                          
   ≤60                    190             89                 101       0.230
   \>60                   209             111                98        
  Gleason score                                                        
   G6--G7                 256             109                147       0.000[\*](#tfn5-medscimonit-25-193){ref-type="table-fn"}
   G8--G10                143             91                 52        
  T-stage                                                              
   T1--T2                 167             70                 97        0.006[\*](#tfn5-medscimonit-25-193){ref-type="table-fn"}
   T3--T4                 232             130                102       
  Lymph node metastasis                                                
   N0                     288             142                146       0.039[\*](#tfn5-medscimonit-25-193){ref-type="table-fn"}
   N1                     54              35                 19        
   Nx                     57              23                 34        
  Grade                                                                
   I--II                  164             67                 97        0.002[\*](#tfn5-medscimonit-25-193){ref-type="table-fn"}
   III--IV                235             133                102       
  PSA value                                                            
   0--4 ng/ml             375             182                193       0.019[\*](#tfn5-medscimonit-25-193){ref-type="table-fn"}
   \>4 ng/ml              24              18                 6         

Two-tailed fisher's exact test was done with the SPSS software program to determine the statistical significance of the level of expression of SETD5 in different clinical characteristics,

p.value \<0.05 was considered significant.
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